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Abstract
Statistical models have greatly improved our understanding of the pathogenesis of HIV-1 infection
and guided for the treatment of AIDS patients and evaluation of antiretroviral (ARV) therapies.
Although various statistical modeling and analysis methods have been applied for estimating the
parameters of HIV dynamics via mixed-effects models, a common assumption of distribution is
normal for random errors and random-effects. This assumption may lack the robustness against
departures from normality so may lead misleading or biased inference. Moreover, some covari-
ates such as CD4 cell count may be often measured with substantial errors. Bivariate clustered
(correlated) data are also commonly encountered in HIV dynamic studies, in which the data set par-
ticularly exhibits skewness and heavy tails. In the literature, there has been considerable interest in,
via tangible computation methods, comparing different proposed models related to HIV dynamics,
accommodating skewness (in univariate) and covariate measurement errors, or considering skew-
ness in multivariate outcomes observed in longitudinal studies. However, there have been limited
studies that address these issues simultaneously.
One way to incorporate skewness is to use a more general distribution family that can provide
flexibility in distributional assumptions of random-effects and model random errors to produce ro-
bust parameter estimates. In this research, we developed Bayesian hierarchical models in which the
skewness was incorporated by using skew-elliptical (SE) distribution and all of the inferences were
carried out through Bayesian approach via Markov chain Monte Carlo (MCMC). Two real data set
from HIV/AIDS clinical trial were used to illustrate the proposed models and methods.
This dissertation explored three topics. First, with an SE distribution assumption, we compared
models with different time-varying viral decay rate functions. The effect of skewness on the model
fitting was also evaluated. The associations between the estimated decay rates based on the best
fitted model and clinical related variables such as baseline HIV viral load, CD4 cell count and long-
term response status were also evaluated. Second, by jointly modeling via a Bayesian approach,
we simultaneously addressed the issues of outcome with skewness and a covariate process with
vi
measurement errors. We also investigated how estimated parameters were changed under linear,
nonlinear and semiparametric mixed-effects models. Third, in order to accommodate individual
clustering within subjects as well as the correlation between bivariate measurements such as CD4
and CD8 cell count measured during the ARV therapies, bivariate linear mixed-effects models with
skewed distributions were investigated. Extended underlying normality assumption with SE distri-
bution assumption was proposed. The impacts of different distributions in SE family on the model
fit were also evaluated and compared.
Real data sets from AIDS clinical trial studies were used to illustrate the proposed method-
ologies based on the three topics and compare various potential models with different distribution
specifications. The results may be important for HIV/AIDS studies in providing guidance to better
understand the virologic responses to antiretroviral treatment. Although this research is motivated
by HIV/AIDS studies, the basic concepts of the methods developed here can have generally broader
applications in other fields as long as the relevant technical specifications are met. In addition, the
proposed methods can be easily implemented by using the publicly available WinBUGS package,
and this makes our approach quite accessible to practicing statisticians in the fields.
vii
1 Introduction / Literature Review
1.1. Background
The history of human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome
(AIDS) can be traced back to 1981. In California and New York, various doctors reported that a
small number of homosexual men had been diagnosed with rare forms of Kaposi’s sarcoma and
Pneumocystis carinii pneumonia, which are generally found in people with seriously compromised
immune systems. By mid 1982, it was clear that they were more than isolated incidents and in
September of that year, Centers for Disease Control and Prevention (CDC) used the term AIDS as
an official diagnosis for this disease. Soon it was realized people could get HIV if they engaged in
certain activities such as having unprotected sex, sharing needles, receiving a blood transfusion and
if they were born to a mother with HIV infection.
HIV infection is considered as a pandemic by the World Health Organization (WHO). By the
end of 2010 (UNAIDS 2011), an estimated 34 million people were living with HIV, up 17% from
2001. Approximately 16.8 million are women and 3.4 million are less than 15 years old. The
estimated prevalence of HIV varies dramatically among regions: the most affected region is Sub-
Saharan Africa and it accounts 68% HIV cases and 66% of HIV deaths; about 5% of the adult
population in this area is infected. Prevalence is the lowest in Western and Central Europe (0.2%)
and East Asia (0.1%). With the significant expansion of HIV prevention programs and access to
antiretroviral therapy, the number of new infections and HIV/AIDS related deaths are decreasing.
In 2010, there were 2.7 million new HIV infections, which was 15% less than in 2001 and 21%
less than the number of new infections that occurred at the peak of the epidemic in 1997, and there
were 1.8 million AIDS related deaths, which was 18% less than in 2001. In the United States, since
the beginning of the HIV and AIDS epidemic, over half a million people have died of AIDS, and
currently around 1.2 million people are living with HIV, however 20% of them are unaware of their
infection.
HIV belongs to a class of viruses known as retroviruses. Retroviruses use ribonucleic acid
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(RNA) to encode their genetic information and RNA is translated into deoxyribonucleic acid (DNA)
during its life-cycle by a specific viral enzyme called reverse transcriptase. Viruses cannot grow
or reproduce on their own so they must infect cells of a living organism in order to survive and
make new copies. There are two types of HIV, HIV-1 and HIV-2, and both originated through
the evolution of simian immunodeficiency virus (SIV). Although both types can be transmitted
by sexual contact, blood, and from mother to child, compared with HIV-2, HIV-1 is more easily
transmitted and patients with HIV-1 infection will more quickly progress to AIDS. Therefore, it is
responsible for the majority of global HIV infections and AIDS cases.
Figure 1.1: Diagram of HIV.
HIV virion is roughly spherical and has a diameter of about 1/10,000 mm, which is 60 times
smaller than a red blood cell. As Figure 1.1 shows, the basic structure of HIV includes: (i) a lipid
membrane. It is the outer envelope of the virus and consists of two layers of lipids. Different
proteins are embedded in this viral envelope and form ”spikes” consisting of glycoprotein (gp) 120
and transmembrane gp41. Gp120 is needed to attach the virion to the host cell, and gp41 is critical
for the cell fusion process; (ii) the HIV matrix proteins. They lie between the envelope and core; (iii)
the viral core. It contains the viral capsule protein p24 which surrounds two single strands of RNA
and the enzymes needed for HIV replication, such as reverse transcriptase, protease, ribonuclease,
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and integrase. Among the nine virus genes coded on one long stand of RNA, three genes, gag, pol
and env, contain information needed to make structural proteins for new virus particles.
Figure 1.2: HIV replication.
There are six steps involved in HIV infection and replication (Figure 1.2). Step 1: binding and
entry. By binding specific receptors on the surface of a target cell, such as CD4 positive T cells (i.e.,
CD4 cells), macrophages and microglial cells, HIV enters the host cells. The CD4 receptor is neces-
sary but not sufficient to permit virus entry. The secondary receptors are “chemokine receptors” that
bind to chemokines and are needed to facilitate the entering (Dragic et al., 1996); Step 2: reverse
transcription. HIV uses an enzyme known as reverse transcriptase to convert its RNA into DNA;
Step 3: integration. HIV DNA enters the nucleus of the target cell and inserts itself into the cell’s
DNA, where it may “hide” and stay inactive for years; Step 4: transcription. HIV DNA instructs the
cell to make many copies of the original virus, along with some more specialized genetic materials
for making longer proteins; Step 5: assembly. A special enzyme called protease cuts the longer HIV
proteins into individual proteins. When these come together with the virus genetic material, a new
virus is assembled; Step 6: release. The virus pushes itself out of the host cell and takes with it part
of the cell membrane. This outer part covers the virus and contains all of the structures necessary
for the virus to bind to a new CD4 cell and begin the virus life cycle process again. Knowing these
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steps is critical in the development of medications that can interrupt the replication cycle. Current
treatment strategy involves a combination of drugs that target different steps of HIV’s life cycle such
as entry inhibitors that prevent binding of HIV to the CD4 receptor, reverse transcriptase inhibitors
that prevent the HIV RNA from being transcribed into DNA and protease inhibitors that prevent the
assembly.
Figure 1.3: A generalized graph of the relationship between HIV copies and CD4 cell count over
the average course of untreated HIV infection.
HIV infection generally can be broken into four stages: primary infection, clinical latency
(asymptomatic) stage, symptomatic stage and AIDS (Figure 1.3). Stage 1: primary infection. This
stage can last for a few weeks and patients are often accompanied by a short flu-like symptom, such
as headache, nausea, sore throat or fever. During this stage, the amount of HIV in the peripheral
blood increases sharply and the immune system starts to respond to the virus by producing HIV
antibodies and cytotoxic lymphocytes. This process is known as “seroconversion”. Since enzyme-
linked immunosorbent assay (ELISA), which is the most commonly used method to test for HIV,
uses blood, oral fluid or urine to detect HIV antibodies, the result may be negative if the ELISA
test is done before seroconversion is complete. There is a corresponding decrease in the number of
CD4 cells and an increase in CD8 cells. Patients are extremely infectious during this stage. Stage
2: clinically asymptomatic stage. This stage lasts for an average of ten years and patients are free
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from major symptoms, although some may have swollen glands. During this stage, the immune
system is able to mount an effective response, so the viral load starts to decrease and then stays
at a constant low level. The number of CD4 cells rises and then slowly falls. People remain in-
fectious and HIV antibodies are detectable in the blood so the antibody test will show a positive
result. Although the viral load remains at a constant low level for years, virus replication is very
active during this period. Stage 3: symptomatic HIV infection. Eventually, the immune system is
severely damaged or “burned out” by years of activity. HIV mutates and becomes more pathogenic
leading more immune cells destruction, while the body fails to keep up with replacing the lost cells.
Symptomatic HIV infection is mainly caused by opportunistic infections that the normal immune
system usually would prevent. This stage of HIV infection is often characterized by multi-system
diseases and infections occurring in almost all body systems. Without any effective treatment, the
immune suppression will continue to worsen. Stage 4: AIDS. Once the CD4 cell count is less than
200/mL or CD4 cell percentage is less than 15, AIDS will be diagnosed.
The CD4 cell, the major target cell for HIV, is a T lymphocytes. Under the microscope, lym-
phocytes can be divided into large and small lymphocytes. Large lymphocytes include natural killer
(NK) cells, while small lymphocytes consist of T cells that mature from thymus and B cells that are
bursa-derived. T cells are involved in cell-mediated immunity whereas B cells are primarily respon-
sible for humoral immunity (relating to antibodies). The CD4 cell is a subset of T cells that express
the cluster of differentiation 4 (CD4) and it is also known as T helper cell. These cells assist other
white blood cells in immunologic processes. The normal CD4 cells account for 32% to 68% of
total number of lymphocytes and range between 500 – 1600/mL. Without effective HIV treatment,
the hallmark decrease in CD4 cells that occurs during AIDS results in such a weakened immune
system that the body can no longer fight infections or certain cancers, and eventually death ensues.
The mechanisms of CD4 cell death in HIV infection are still not fully understood and are one of
the most controversial issues in AIDS research. The mechanisms by which HIV can directly induce
infected cell death include plasma membrane disruption or increased permeability due to continu-
ous budding of the virion (Facui, 1988), increasing cellular toxicity due to build up of un-integrated
liner viral DNA (Levy, 1993) and inactivation of anti-apoptotic genes (Nie et al., 2002). However,
a longstanding question in HIV biology is how HIV viruses kill so many CD4 cells, despite the fact
that most of them appear to be “bystander” cells that are not infected (Embretson et al., 1993). Re-
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cent data demonstrate that the majority uninfected CD4 cells in peripheral blood and lymph nodes
undergo three types of apoptosis (Varbanov et al., 2006), which is a tightly regulated programmed
cell death (Evan et al., 1998). Several HIV proteins, such as Env and Vpr, have been found to be
able to up-regulate Fas/FasL gene expression either on the infected cells or neighboring uninfected
cells (Kaplan and Sieg, 1998), and these two genes will send signal of apoptosis to these cells.
CD8 cell is another type of T cell. It destroys virally infected cells and tumor cells so it is
also known as cytotoxic T cell (Tc cells or CTLs). A healthy adult usually has 150 – 1,000/mL
CD8 cells and the normal ratio of CD4/CD8 is 1.0 – 3.7. In contrast to CD4 cells, CD8 cells often
increase in people with HIV and the significance has not been well understood. Researches have
revealed (Chevret et al., 1992; Krantz et al., 2011) that elevated total CD8 cell count was associated
with greater risk of future virologic failure. The CD4/CD8 Ratio is used to help in diagnosing HIV,
monitoring HIV progress, and making treatment decisions.
HIV diagnostic test is done by either detecting host antibodies made against different HIV pro-
teins or by directly detecting the whole virus or components of virus (Iweala, 2004). Tests that
detect host antibodies that are specific to the virus include ELISA, Western blot, the immunofluo-
rescence assay (IFA), and the detuned assay. For screening purposes, ELISA is usually used first,
and in order to minimize the risk of false positive results, a confirmatory test, such as Western blot
or IFA, should be conducted before a patient is given the diagnosis of HIV infection. Detuned
assay is used to distinguish recent HIV infection within the past 129 – 180 days from older HIV
infections (Parekh et al., 2002). These tests may be negative during the acute infection or before
seroconversion is completed. In contrast, three types of tests can directly detect the virus or parts
of the virus as soon as people become infected with HIV. These tests include p24 antigen detec-
tion, peripheral blood mononuclear cell culture and RNA nucleic acid-based assays, such as reverse
transcription followed by polymerase chain reaction (RT-PCR) and hybridization-based assays. Un-
detectable viral load is usually defined as less than 50 copies/ml. Until recently, this was the lowest
detectable level for the commonly used tests in routine viral load monitoring. There are now some
ultra-sensitive tests that can measure less than 20 copies/ml and even 1 copy/ml of plasma (Palmer
et al., 2003).
It takes an average of 10 years after HIV infection to develop AIDS, and the viral load generally
remains unchanged if measured repeatedly during those years. Originally, many people thought
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the rate of HIV replication and disease process would be slow, which is not true. In 1995 and
1996, several important papers (Ho et al., 1995; Perelson et al., 1996; Wei et al., 1995) published
in prestigious journals showed that HIV replication and the disease process are very vibrant. On
average, plasma virions have a mean lifespan of 0.3 days (half-life = 0.24 days), and the average
total HIV-1 production is 10.3 × 109 per day, the minimum duration of the HIV-1 life cycle in vivo
is 1.2 days, and the average HIV-1 generation time is 2.6 days (generation time is defined as the
time from release of a virion until it infects another cell and causes the release of a new genera-
tion of viral particles.) Because the high viral replication rate may result in a high mutation rate,
Ho (1995) proposed the treatment strategy of “Hit Hard, Hit Early”. “Hit Hard” requires simulta-
neously combining different medications in the treatment, while “Hit Early” means the treatment
should start as early as HIV infection has been confirmed. Although the so called “cocktail” treat-
ment approach proposed by Ho is still the most commonly used treatment strategy, “Hit Early”
was abandoned quickly when clinicians realized the adverse effects outweighed the benefits. The
treatment should be “Hit HIV-1 hard, but only when necessary” (Harrington et al., 2000). Based on
2012 U.S. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults
and Adolescents (Guidelines, 2012), the initiation of antiretroviral therapy (ART) is optional if the
CD4 cell count is > 500 /mL, moderately recommended if the CD4 cell count is 350 to 500 /mL
and strongly recommended if the value is < 350 /mL. Regardless of the CD4 cell count, ART is
strongly recommended if patients have certain conditions such as pregnancy, history of an AIDS
defining illness or hepatitis B (HBV) co-infection. The usual highly active antiretroviral therapy
(HAART) combines three or more different medications such as two nucleoside reverse transcrip-
tase inhibitors (NRTIs) and a protease inhibitor (PI), a non-nucleoside reverse transcriptase inhibitor
(NNRTI) or other such combinations. These HAART regimens have been proven to be able to re-
duce the amount of active viruses and in some cases can lower the number of active viruses until it
is undetectable by current blood testing techniques.
1.2. HIV dynamic models
The basic model for HIV infection includes three parts: target uninfected cell T, virus V and infected
cell T ∗. The equations that describe the basic model of viral dynamics before the treatment are:
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dT
dt = ρ− dT − kV T
dT ∗
dt = kV T − δT ∗
dV
dt = ηT
∗ − cV
(1.1)
where T is produced at a rate of ρ and dies at rate d, virus V is cleared from the body at rate c and
infects the target cells T to T ∗ at rate of k, infected cell T ∗ dies at rate δ and produces new virus
particles at a constant rate η. This is a system of nonlinear ordinary differential equations (ODE)
without any closed form solution, however, we can derive various approximations and obtain an
understanding of the system.
Before infection, V = 0 , T ∗ = 0 and uninfected cells T are at equilibrium as T = ρ/d. Denote
by t = 0 is the time when infection occurs. Suppose infection occurs with a certain amount of
virus, so the initial conditions are T0 = ρ/d , T ∗0 = 0 and V0. Similar as the condition that spread of
an infectious disease in a population, whether or not the virus can grow and establish an infection
depends on a crucial quantity called basic reproductive ratio R. R is defined as the number of newly
infected cells arising from one infected cell when almost all cells are uninfected and R = ρkηdδc .
If R < 1 then the virus will not spread, because every infected cell will on average produce less
than one other infected cell. If starting with N infected cells, then on average, we expect roughly
lnN/ ln(1−R) rounds of replications before the virus population dies out. If on the other hand, R
> 1, then, on average, every infected cell will produce more than one newly infected cell. The chain
will generate an explosive multiplication of virus as V (t) = V0 exp(rt), where r is the exponential
growth rate of the virus population and it is given by the larger root of the equation r2 +(δ + c)R
+δc(1 − r2) = 0, the approximation of r = δ(R − 1), which means each infected cell produces R
newly infected cells before dying. Virus growth will not continue indefinitely because the supply of
uninfected cells is limited.
During the short time since initiation of HAART treatment, the viral load decrease sharply. This
change with time can be expressed by the differential equation as, dV/dt = P − λV , where P is
the viral production rate, λ is the decay rate of viral load, and V is the HIV viral load in plasma. If
assuming a pretreatment steady state exists, dV/dt = 0, and a perfect treatment effect that no new
infection or new virion produced, the HIV dynamics can be expressed as a simple one-exponential
equation (Ho et al., 1995):
V (t) = V (0) exp(−λt) (1.2)
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where V (t) is the viral load at time t and V (0) is the viral load at the baseline. Equation (1.2) can
only reasonably describe the behavior of the viral dynamics during 1–2 weeks after the initialization
of treatment.
Assuming a perfect protease inhibitor treatment effect (Perelson et al., 1996), which means no
new infectious virions (VI ) but some noninfectious virions (VNI ) will still be produced, the HIV
dynamics can be expressed as the following system of ODE:
dT ∗
dt = kVIT − δT ∗
dVI
dt = −cVI
dVNI
dt = NδT
∗ − cVNI
(1.3)
where N is the number of new virions produced per infected cell during its life time. Under the
assumption of constant supply of target cell T and quasi-steady state before treatment (dT ∗/dt = 0
and dV/dt = 0), a close form solution to the system of ODE (1.3) can be obtained:
V (t) = V0 exp(−λt) + λV0λ−δ × [ λV0λ−δ{exp(−δt)− exp(−λt)} − δt exp(−λt)] (1.4)
where V (t) = VI(t) + VNI(t), Perelson et al.(1996) applied equation (1.4) to more frequent mea-
sured HIV-1 RNA data during the first week of treatment. By nonlinear least-squares regression,
the estimated half-life of free virions is about six hours and it is 1.6 days for productively infected
cells.
Perelson et al.(1997) further extended the ODE (1.3) in order to include a longer period of treat-
ment that a biphasical decay rate of plasma HIV-1 RNA was observed: an initial rapid exponential
decline of nearly 2-logs (first phase), followed by a slower exponential decline (second phase). Two
more target cells are added in the model: (i) long-lived infected cells, macrophages (M), will be
infected into M∗ with a rate of kM , produce virions at rate of p and die with a rate of µM ; (ii)
latently infected lymphocytes (L) will be produced by a rate constant fk and die at a rate of µL.
The HIV dynamics can be expressed as:
dT ∗
dt = kV T + αL− δT ∗
dL
dt = fkV T − µLL
dM∗
dt = kMVM − µMM∗
dV
dt = NδT
∗ + pM∗ − cV
(1.5)
where latent infected cells L can become productively infected cells at rate of α. With the similar
assumptions used for equation (1.4), a closed form solution to the system of ODE (1.5) is,
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V (t) = V0[A exp(−δt) +B exp(−µLt) + C exp(−µM t) + (1 +A+B + C)] (1.6)
where A, B and C are functions of system parameters. Even with additional peripheral blood
mononuclear cells information, this equation is too complicated to identify all parameters, there-
fore, some parameters are assumed to be known and replaced by the values from previous studies.
The first six weeks since the treatment was used in equation (1.6) and the half-life of productively
infected CD4 cells, long-lived infected cells and latently infected cells were estimated as 1.1 days,
14.1 days and 8.5 days, respectively.
Perfect treatment effect may not be a very reasonable assumption, especially after short period
of treatment. Wu and Ding (1999) proposed a system of ODE that included a protease inhibitor
efficacy parameter of γ, 0 ≤ γ ≤ 1, while γ = 0 means the PI medications have no effect and
γ = 1 means perfect effect. The original ODE they proposed included many parameters that either
can be negligible if they are associated with the faster decays or can be approximated by constants if
they are slow enough in the modeling time period or if they are impossible to be accurately estimated
based on the HIV-1 viral load available. The simplified system of ODE Wu and Ding proposed is:
d
dtT
∗ = kVIT − δT ∗
d
dtVI = (1− γ)P − cVI
d
dtVNI = γP + P
∗ +NδT ∗ − cVNI
(1.7)
where P is the virus produced rate by productively infected cells, such as CD4 cell, P ∗ accounts
for virus produced from “mysterious” infected cells such as Langerhans cells and microglial cells,
or long-lived infected cells such as macrophages and latent infected cells, and k, T ∗, δ, VI , VNI , N
and c have the same meaning as ODE (1.3). A closed form solution to the system of ODE (1.7) is,
V (t) = exp(P1 − λ1t) + exp(P2 − λ2t) + (P3 + P4t) exp(−ct)
where V (t) = VI(t) + VNI(t), λ1 = δ and it is the first-phase viral decay rate that may represent
the minimum turnover rate of productively infected cells, such as CD4, λ2 is a possibly compound
clearance rate of long-lived and latently infected cells and the value depends on the infection rate
and destroyed rate by HIV virus. Because c has been estimated to be very rapid (less than 6 hours
of half life), it can be negligible compared with other terms. Thus, the equation can be further
simplified as a two-exponential equation:
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V (t) = exp(P1 − λ1t) + exp(P2 − λ2t) (1.8)
where P1 and P2 is initial viral production rate from productively infected cells, long-lived and
latently infected cells, respectively. Nonlinear mixed-effects (NLME) modeling can be used in the
estimation of the parameters in equation (1.8). NLME modeling will pool individual data together
to estimate the population parameters first, then estimate the individual parameters by the empirical
Bayesian method (Vonesh and Chinchili, 1996).
Although the “cocktail” HAART treatment can suppress HIV in 60 to 90% of cases, 30 to 60%
of patients will end up as being considered treatment failure eventually because of the viral load
rebound (Havlir et al., 2000). However, all of the equations introduced so far require the decay rate
to be constant so they can’t be applied to rebound values. Several extensions have been developed
in order to catch up viral load response that include rebound data and three representatives are
following:
(i) Extended from the ODE (1.1), Huang et al.(2003) proposed a viral dynamic model with a
time varying treatment efficacy function γ(t) as,
dT
dt = ρ− dT − [1− γ(t)]kTV
dT ∗
dt = [1− γ(t)]kTV − δT ∗
dV
dt = NδT
∗ − cV
where γ(t) represents a time varying treatment efficacy and it can be modeled as a function
of drug exposure and drug sensitivity.
(ii) Extended from one exponential equation (1.2) by replacing the constant decay rate with a
time varying decay function (Wu, 2004):
V (t) = V (0) exp(−λ(t)t)
(iii) Extended from two exponential (1.8) by replacing the second constant decay rate with a time
varying decay rate function as (Wu and Zhang, 2002):
V (t) = exp(P1 − λ1t) + exp(P2 − λ2(t)t)
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Among these three extensions, the first one is a system of nonlinear ODE without a closed form, so
compared with the other two, the computation is even more challengeable and the model may not
converge, therefore, we will focus on either the one exponential or two exponential equation in the
Chapter 2 and 3.
HIV progress status is usually measured via HIV viral load or CD4 cell count, which are both
surrogate biomarkers. CD4 cell count is more often used as an endpoint for long follow-up trials or
advanced patients population, but for trials with short follow-up periods, viral load is often used as a
primary endpoint to quantify treatment effect, where CD4 cell count is viewed as a covariate to help
predict virologic responses. However, we should be aware the possible issues of using either HIV
viral load or CD4 cell count as the outcome. The possible troublesome aspects of using the viral
load as the primary outcome include (i) if the viral load is measured by RT-PCR which is based
on the viral fragments, the result may overestimate the number of infectious virus by an average
factor of 60,000 (Nowak et al., 1991); the lack correlation between of viral load and infection was
also noted in some publications (Perelson et al., 1993; 1999), where no evidence of virus by culture
among the patients with detectable viral load; (ii) the lack of correlation between viral load and
CD4 level such that the changes in viral load were only able to explain as little as 4% of change
in the CD4 cell count (Rodriguez et al., 2006). Although CD4 cell count seems to be a better HIV
progression indicator, especially for the study with a longer follow-up period, prediction may be
risky since CD4 cell count models are often empirical (Wu and Ding, 1999; Wu, 2002). On the
other hand, treating both viral load and CD4 cell count as a bivariate response (Sy et al., 2007) may
be complicated, because the HIV dynamic model for viral load is nonlinear and CD4 cell count
contains missing data.
1.3. Statistical inference in HIV dynamics
Various statistical inferences and analysis methods have been applied in HIV dynamics. Linear and
nonlinear regression via least-squares (LS) estimation can be applied to very frequent measurements
during the first 1 – 2 weeks after the treatment is initiated (Ho et al., 1995; Perelson et al., 1996;
1997; Wei et al., 1995). Because frequent viral load measurement is only achievable in small
clinical studies and only subjects without any missing values can be included in LS, this method is
considered to be less powerful than some other inferences.
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Because viral load are measured repeatedly since the treatment, the values obtained from the
same subject may be correlated but can be assumed to be independent if obtained from different
subjects. One powerful tool to handle such longitudinal data is mixed-effects modeling, in which
within-subject and between-subject variations are both considered (Laird and Ware, 1982). Linear
mixed-effects (LME) and nonlinear mixed-effects (NLME) modeling approaches have been pro-
posed in HIV dynamics (Wu et al., 1998; 2004; Wu and Ding, 1999). Semiparametric nonlinear
mixed-effects (SNLME) modeling (Liu and Wu, 2007; Wu and Zhang, 2002; Wu et al., 2004) is
proposed in order to allow the decay rate to vary with time so the rebound viral load can be included.
Joint model approach via Monte Carlo EM algorithm can be applied to the NLME with covariate
measurement errors and non-ignorable missing responses (Liu and Wu, 2007; Wu, 2002; 2004). Es-
timation of NLME is complex because usually the likelihood has no closed form solution, even for
simple models. The Bayesian approach based on Markov chain Monte Carlo (MCMC) algorithm
has been proposed for complex ODE and NLME (Huang et al., 2006; Huang and Dagne, 2011;
2012a; 2012b; Putter et al., 2002; Wu et al., 2005). To avoid the numerical computation of multiple
integrals involved in the likelihood, likelihood approximation such as linearization, Laplace ap-
proximation, Stochastic approximation EM algorithm (SAEM) have been applied in HIV dynamics
(Ding and Wu, 2000; Guedj et al., 2007; Kuhn and Lavielle, 2005; Wu, 2004).
Another complexity of viral load analysis is left censoring which occurs when viral loads are
below a limit of qualification (LOQ), and if ignored, the censoring may induce biased parameter
estimates. Different approaches have been proposed to address this problem (Fitzgerald et al., 2002;
Hughes, 1999; Lavielle et al., 2011; Samson et al., 2006; Thie´baue et al., 2005).
The model random errors and random-effects in mixed-effect models are usually assumed to
have a normal distribution and that assumption may not be satisfied in HIV viral load and CD4
cell count, so the estimation can be biased. Skewed distribution can be applied in order to consider
this non-ignorable departure from normality (Huang et al., 2006; Huang and Dagne, 2012a; 2012b;
Dagne and Huang, 2012).
CD4 and CD8 cell count can be used as surrogate biomarkers for HIV disease process. Shah
et al.(1997) used an EM algorithm to fit a bivariate linear random-effects model. Sy et al.(1997)
used the Fisher scoring method to fit a bivariate linear random-effects model including an integrated
Orstein-Uhlenbeck process (IOU). IOU is a stochastic process that includes Brownian motion as a
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special limiting case.
1.4. Skew-elliptical distributions
Linear and nonlinear mixed-effect models are powerful tools for analyzing repeated measures and
clustered data. In these models, random-effects are included in order to account correlation. Usually
either random-effects or model errors or both are assumed to follow a normal distribution. Although
normality assumption may be reasonable for many situations, the skewness can still be obvious even
after the variables have been transformed. Ignoring the departure from normality may cause biases
or misleading results (Ghosh et al., 2007; Verbeke and Lesaffre, 1996). Ideally, we hope to use a
more generalized distribution family that (i) has high flexibility in shapes and with a wide range of
skewness and kurtosis; (ii) is mathematically tractable, which means it can retain nice properties
of original family such that parameters can be directly linked to some aspects of known probability
density function (pdf); (iii) allows us to easily apply the distributions in the existing software.
Skew-elliptical (SE) distribution is a parametric class of probability distributions that is ex-
tended from elliptical distribution by including an additional shape parameter for skewness. This
class, which is usually obtained by using transformation and conditioning, contains many standard
families such as multivariate skew-normal (SN), skew-t (ST), Student-t and normal distributions.
Different versions of the multivariate SE distributions have been proposed. The version proposed
by Azzalini et al.(1996; 1999) is based on conditioning one suitable random variable being greater
than zero; SE distribution proposed by Jones and Faddy (2003) is scaled inverse χ distribution;
Fernandez and Steel (1998) developed a form that two Student-t distributions (with different scale
parameters) in positive and negative domains are combined to form an SE distributions; We adopt
a class of multivariate SE distributions proposed by Sahu et al.(2003), which is obtained by using
transformation and conditioning, contains multivariate ST , SN, Student-t and normal distribution
as special cases. A k-dimensional random vector Y follows a k-variate SE distribution if its pdf is
given by
f(y|µ,Σ,∆;m(k)ν ) = 2kf(y|µ,A;m(k)ν )P (V > 0) (1.9)
where A = Σ + ∆2, µ is a location parameter vector, Σ is a covariance matrix, ∆ is a skew-
ness diagonal matrix with the skewness parameter vector δ = (δ1, δ2, . . . , δk)T , V follows the el-
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liptical distribution El
(
∆A−1(y − µ), Ik −∆A−1∆;m(k)ν
)
and the density generator function
m
(k)
ν (u) =
Γ(k/2)
πk/2
mν(u)∫
∞
0 r
k/2−1mν(u)dr
, with mν(u) being a function such that
∫∞
0 r
k/2−1mν(u)dr
exists. The function mν(u) provides the kernel of the original elliptical density and may depend
on the parameter ν. We denote this SE distribution by SE(µ,Σ,∆;m(k)ν ). Two examples of
mν(u), leading to important special cases used throughout the paper, are mν(u) = exp(−u/2) and
mν(u) = (u/ν)
−(ν+k)/2
, where ν > 0. These two expressions lead to the multivariate SN and ST
distributions, respectively. In the latter case, ν corresponds to the degree of freedom parameter.
1.4.1. Skew-t distribution
We briefly discuss a multivariate ST distribution introduced by Sahu et al.(2003) in this section. A
k-dimensional random vector Y follows a k-variate ST distribution if its pdf is given by
f(y|µ,Σ,∆, ν) = 2ktk,ν(y|µ,A)P (V > 0) (1.10)
we denote the k-variate t distribution with parameters µ,A and degrees of freedom ν by tk,ν(µ,A)
and the corresponding pdf by tk,ν(y|µ,A) henceforth, V follows the t distribution tk,ν+k. We
denote this distribution by STk,ν(µ,Σ,∆). In particular, whenΣ = σ2Ik and ∆ = δIk, equation
(1.10) simplifies to
f(y|µ, σ2, δ, ν) = 2k(σ2 + δ2)−k/2 Γ((ν+k)/2)
Γ(ν/2)(νπ)k/2
{
1 +
(y−µ)T (y−µ)
ν(σ2+δ2)
}−(ν+k)/2
×Tk,ν+k
[{
ν+(σ2+δ2)−1(y−µ)T (y−µ)
ν+k
}−1/2 δ(y−µ)
σ
√
σ2+δ2
]
where Tk,ν+k(·) denotes the cumulative distribution function (cdf) of tk,ν+k(0, Ik). However, un-
like in the SN distribution below, the ST density can not be written as the product of univariate ST
densities. Here Y are dependent but uncorrelated.
The mean and covariance matrix of the ST distribution STk,ν(µ, σ2Ik,∆) are given by
E(Y ) = µ+ (ν/π)1/2 Γ((ν−1)/2)Γ(ν/2) δ, cov(Y ) =
[
σ2Ik +∆
2
]
ν
ν−2 − νπ
[
Γ{(ν−1)/2}
Γ(ν/2)
]2
∆
2
The ST distribution of Y has two types of stochastic representation as follows, and each pro-
vides a convenience device for random number generation and implementation purpose.
(i). By the proposition of Sahu et al.(2003),
Y = µ+∆|X0|+Σ1/2X1 (1.11)
where X0 and X1 are two independent random vectors following tk,ν(0, Ik). Let w = |X0|, then
w follows a k-dimensional standard t distribution tk,ν(0, Ik) truncated in the space w > 0 (i.e., the
standard half-t distribution). Thus, a hierarchical representation of (1.11) is given by
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Y |w ∼ tk,ν+k(µ+∆w, ωΣ), w ∼ tk,ν(0, Ik)I(w > 0) (1.12)
where ω = (ν +wTw)/(ν + k).
(ii) By Proposition 1 of Arellano-Valle et al.(2007), the ST of Y has another convenient stochastic
representation as follows
Y = µ+∆|X0|+ ξ−1/2Σ1/2X1 (1.13)
where |X0| and X1 are two independent Nk(0, Ik) random vectors. Let w = |X0|, then w
follows a k-dimensional standard normal distribution Nk(0, Ik) truncated in the space w > 0.
Thus, following Sahu et al.(2003), a hierarchical representation of 1.13 is given by
Y |w, ξ ∼ Nk(µ+∆w, ξ−1Σ), w ∼ Nk(0, Ik)I(w > 0), ξ ∼ Γ(ρ/2, ρ/2) (1.14)
Note that the ST distribution presented in (1.12) or (1.14) can be reduced to the following three
special distributions:
(a). An SN distribution SNk(µ,Σ,∆) as ν → ∞ and ξ → 1 with probability of 1 (based on
equation of 1.14) or as ν →∞ with probability of 1 (based on equation of 1.12);
(b). A Student-t distribution tk,ν(µ,Σ) as∆ = 0;
(c). A normal distribution Nk(µ,Σ) if both conditions of (a) and (b) are satisfied.
In order to better understand the shape of an ST distribution, plots of an ST density as a function
of the skewness parameter with δ = −3, 0, 3 are shown in Figure 1.4(a).
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Figure 1.4: The univariate skew-t (df ν = 4) and skew-normal density functions with precision
σ2 = 1 and skewness parameter δ = 0, -3 and 3, respectively.
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1.4.2. Skew-normal distribution
We briefly discuss a multivariate SN distribution introduced by Sahu et al.(2003) in this section. A
k-dimensional random vector Y follows a k-variate SN distribution, if its pdf is given by
f(y|µ,Σ,∆) = 2k|A|−1/2φk{A−1/2(y − µ)}P (V > 0), (1.15)
where V ∼ Nk{∆A−1(y − µ), Ik −∆A−1∆}, and φk(·) is the pdf of Nk(0, Ik). We denote
the above distribution by SNk(µ,Σ,∆). An appealing feature of equation (1.15) is that it gives
independent marginal when Σ = diag(σ21 , σ22 , . . . , σ2k). The pdf (1.15) thus reduces to
f(Y |µ,Σ,∆) =∏ki=1
[
2√
σ2i+δ
2
i
φ
{
yi−µi√
σ2i+δ
2
i
}
Φ
{
δi
σi
yi−µi√
σ2i+δ
2
i
}]
,
where φ(·) and Φ(·) are the pdf and cdf of the standard normal distribution, respectively.
The mean and covariance matrix are given by
E(Y ) = µ+
√
2/πδ, cov(Y ) = Σ+ (1− 2/π)∆2
It is noted that when ∆ = 0, the SN distribution reduces to usual normal distribution. In
addition, the SN distribution is a special case of the ST distribution. That is, the ST distribution
reduces to the SN distribution when the degree of freedom is large. In order to better understand
the shape of an SN distribution, plots of an SN density as a function of the skewness parameter with
δ = −3, 0, and 3 are shown in Figure 1.4(b).
1.5. Specific aims
A common assumption in mixed-effect model for random errors and random-effects is normal dis-
tribution. This assumption may lack robustness against departure from normality and can be greatly
affected by outliers too, therefore, the results may be somewhat misleading. In HIV/AIDS studies,
the viral load, CD4 and CD8 cell count can exhibit obvious skewness, even after transformation.
It will be valuable to explore whether a general skewed distribution such as ST or SN will bring
a better model fitting. Also due to the nature of HIV dynamics, the related models can be very
complicated and associated intensive computation burden in the inference. Non-convergence of the
algorithms may exist under the framework of likelihood estimation. Besides these issues, there are
at least three specific questions that have not been satisfactorily answered:
First, it is important to use entire HIV viral load data to have a better understand about the disease
progress and to compare the effect of different medications. However, among all of those
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models that can be applied to include the rebound data, it is unclear which one is preferred, or
whether different distributions will affect the model fit, or whether the estimated parameters
can be good predictors for some long-term result as as treatment failure.
Second, in order to explain individual difference in HIV dynamics, covariates, such as CD4, are often
used in the model. However, CD4 values may be measured with substantial errors or at a
different schedule as the viral load measurement. Also, LME, NLME and SNLME can be
used for short, middle and long term of HIV dynamics data, respectively. Although they have
some of the same parameters such as the first decay rate which is the minimal turn over of
the productively infected cells, it is unclear whether this estimation obtained from different
models is constant, and if not, which model will yield more reasonable estimations.
Third, using HIV viral load as a surrogate to predict the disease progress might be problematic. For
example, the amount of infectious virus may be overestimated, therefore, the CD4 cell count
seems to be a better indicator. However, the mechanism by which the CD4 cell count change
during the HIV progress is not clear. Although using bivariate outcomes of CD4 and CD8 cell
count appear to be superior to any of these cell count alone or their ratio (Ir et al., 1990), the
distribution of CD4 and CD8 cell count shows skewness with heavy tails, and no model has
been proposed to consider CD4 and CD8 as outcome simultaneously with skewed distribution
assumption.
Via the Bayesian approach and assuming an SE distribution, this dissertation research is organized
as follow:
Aim 1. Related to the first question of multiple models for entire HIV viral load follow-up, in Chapter
2, we explored different models with time-varying decay rate function in order to find which
one has the best fit. We also assumed different distributions in each model to check the effect
of skewness on the model fit. After finding the best fitted model, we explored the applications
of the estimated decay rate, such as their association with decay rate, CD4 cell count and viral
load rebound status. To the best of our knowledge, no time-varying decay rate function was
checked or had been found to have any significant association with the long-term outcome
such as viral load rebound, although some research found the constant decay rate may reflect
18
the potency of antiviral therapies in the short term. For the purpose of model comparisons,
we used one AIDS clinical trial study data to do the model comparisons and then checked the
validity of the conclusions based on another AIDS clinical trial study.
Aim 2. Related to the second question of covariate with measurement errors and skewness, in Chapter
3, we compared the three most commonly used models for short, middle and long term HIV
dynamics. CD4 was included as an important covariate in the models. A critical question
is whether these models produce coherent estimates of viral decay rates, and if not, which
model is appropriate and should be used in practice. In addition, one common assumption is
that model random errors is normally distributed, but the normality assumption may be un-
realistic, particularly, if the data exhibit skewness. Moreover, some covariates, such as CD4
cell count, may often be measured with substantial errors. We addressed these issues simulta-
neously by jointly modeling the response variable with skewness and a covariate process with
measurement errors. A real data set from an AIDS clinical trial study was used to present the
proposed models.
Aim 3. Related to the third question of CD4 and CD8 as being biomarkers during ARV and con-
sidering their dependence on common predictors, in Chapter 4, we applied a joint bivariate
linear mixed-effects (BLME) model that can include CD4 and CD8 cell count simultaneously
as the outcomes, while the observed skewness in the data was considered by applying an SE
distribution. The baseline viral load, patients’ age, time-varying drug efficacy and the group
of treatments were also included as covariates in the BLME.
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2 Mixed-effects models with skewed distributions for time-varying vi-
ral decay rate in HIV dynamics
2.1. Introduction
Mathematical modeling is an important tool for understanding the evolution of HIV viral load (num-
bers of HIV-1 RNA copies in plasma) and interactions between HIV and its target cells. Most math-
ematical models developed prior to the mid-1990s were created for computer simulations and for
interpreting declines in CD4 cell count after HIV infection. Due to the availability of HAART and
methods of providing sensitive measurement of blood plasma HIV-1 RNA concentrations, it is pos-
sible to use viral load as a surrogate marker for the health status of HIV-infected individuals. The
mathematical modelings of HIV dynamics on the cellular or molecular level are based on a similar
principal used in large-scale epidemiological modeling.
Studies of viral dynamics have a common design, in which the viral load, targeted cells, phar-
macokinetic and pharmacodynamic factors are repeatedly measured since treatment. The viral load
trajectory is complex and has multiple phases of change (Ho et al., 1995; Maldarelli et al., 2007;
Perelson et al., 1997; Wei et al., 1995). Data from A5055 (Acosta et al., 2004) (Figure 2.1) shows
that: (i) within the first 2 weeks after the initial treatment, the viral load (transformed in natural
log scale) dropped linearly and sharply, therefore, the change of viral load can be approximated
by an exponential function; (ii) within the first 2–3 months but after the first 2 weeks, the relation-
ship between the viral load and time was still linear but the slope became flatter, which indicates
a slower decay rate; (iii) between the third to eighth month, the viral load either decreased more
slowly, remained at a constant low level, or started to increase up to the level measured before treat-
ment was initiated. The possible reasons for viral load rebound are development of resistance to
the medications, and other clinical issues such as lack of adherence. There is no clear cutoff among
the phases, not every subject will have all of these phases and the length of the phases may vary
among individuals. Therefore, the associated decay rate in the models for the viral load trajectories
is expected to vary over time and can be individually specific.
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Figure 2.1: Profile of viral load in natural log scale from a clinical trial study-A5055
For the first phase of HIV viral load dynamics (i.e., the first 1 to 2 weeks), we can apply a
uniexponential equation (Ho et al., 1995; Wei et al., 1995) as,
V (t) = V (0) exp(−λt) (2.1)
where V (t) is total viral load at time t, V (0) is the baseline viral load at t = 0 and λ is a constant
viral change rate which is the speed of the loss of viral load after initiation of potent antiviral
treatment. Although equation (2.1) can precisely describe the phenomenon of a linear decrease of
logarithm transformed viral load within approximately one to two weeks since treatment is initiated,
we cannot apply it to the whole trajectory because the viral load is only allowed to decrease at a
constant rate in this equation. Besides that, there are at least three unsolved issues.
First, in order to use entire HIV follow-up data, extended from equation (2.1), different models
have been proposed in the literature, it is unclear which one is more appropriate.
Second, in mixed-effects models for longitudinal data analysis, random errors and/or random-
effects are usually assumed to have a normal distribution. Although the normality assumption is
satisfied in many situations, it may cause biased or misleading inference if the data include ex-
treme values or show skewness with heavy tails, which are commonly seen in virological responses
(Huang and Dagne, 2011; Sahu et al., 2003; Verbeke and Lesaffre, 1996). Figure 2.2 displays the
histogram of repeated viral load in natural log scale for 44 subjects enrolled in the A5055 trial. The
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skewness, which is still obvious even after the transformation, is positive and ranges from 0.8 and
2.15 at each of the follow-up measurements. If the ratio between skewness value and standard error
of skewness is greater than 2, the data may be regarded as having unignorable skewness (Gardner,
2001). In the A5055 study, the ratio is 4 , which indicates skewness needs to be accounted for.
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Figure 2.2: The histogram of viral load (in natural log scale) for 44 patients in a clinical trial study-
A5055
Third, computational infeasibility can be a challenge. Frequentist and Bayesian are two major
approaches used in studies of HIV dynamics. In the frequentist approach, based on the maximum
likelihood estimation (MLE), different extensions have been proposed, such as Laplace approxi-
mation of the numerical integrals (Beal and Sheiner, 1982; Lindstrom and Bates, 1990; Wu and
Zhang, 2002), stochastic approximation EM (SAEM) algorithm (Kuhn and Lavielle, 2005; Lavielle
et al., 2011), joint model via Monte Carlo EM algorithm (Liu and Wu, 2007; Wu, 2004) and asymp-
totic distribution of the maximum h-likelihood estimators (MHLE) (Commenges et al., 2011). The
second approach is Bayesian mixed-effects modeling via MCMC (Huang et al., 2006; Huang and
Dagne, 2011; Putter et al., 2002). The Bayesian approach is an efficient way to incorporate prior
information, both point estimates and uncertainties (variances), into analysis to identify more un-
known parameters in complex models.
Via Bayesian approach, the main focus of this chapter is to provide a comprehensive comparison
of five commonly used HIV dynamic models with SE distribution in random errors. The rest of the
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chapter is organized as follows: Section 2.2 presents the HIV dynamic models that have a time-
varying decay rate function so they can be applied to the entire HIV follow-up data. In Section 2.3,
we describe a general Bayesian mixed-effects modeling approach. In Section 2.4, we present the
motivated AIDS data and results of model comparisons. Section 2.5 includes the conclusion and
discussion.
2.2. HIV dynamic models with time-varying decay rate function
As mentioned in Section 2.1, there is a multiphasic change in HIV viral load after the initiation
of HAART. One potential interpretation of this phenomenon is that the process involves distinct
populations with different homogenous behaviors. For example, the fast decreasing decay rate
observed in the first phase is due to the treatment effect on productively infected CD4 cells, while
the slower decay rate in the second phase is primarily due to the effect on the latently or long-
lived infected cells (Perelson et al., 1997). However, some phenomena can’t be explained by this
theory. For example, there can be large differences in mean decay rates in response to different
treatment regimens: during the first week, the death of infected cells may be substantially slower
during days 3–6 than during days 2–3 (Grossman et al., 1999). If different decay rates reflect
the rates at which different infected cells died, it is unexpected to see that the decay rate should
depend on the type or concentration of the treatment regimen (Mueller et al., 1998). Based on
the assumption that reduced production during immune activation events and fewer cycles account
for the observed multiphasic HIV decrease, Following uniexponential equation (2.1), Grossman et
al.(1999) proposed an equation for viral load as:
V (t) = V (0) exp{− log(R)τ t}
R(v) = R(1) + α(1 − v) exp(−ρv)
v(t) = V (t)/V (0)
(2.2)
where τ is the average infection cycle time, ρ is adjustable parameter, and R is reproduction ratio.
At steady state, R = 1, which means each infected cell is replaced, on average, by one newly
infected cell; V (0) is the baseline viral load; v(t) is the ratio between the viral load at time t and the
baseline. Since V (t) and R depend on each other, this equation may not be easy to solve. Based on
Zhang and Wu (2011), equation (2.2) is equivalent to the equation V (t) = V (0) exp(−λ(t)t), and
λ(t) = log{R(v)}/τ = log{R[V (t)/V (0)]}/τ
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λ(t) is time varying and may be interpreted as the average relative loss rate of the viral load V (t).
Let △t denote a small time period, then the relative loss rate α(t) is:
α(t) = lim△t→∞{V (t)−V (t+△t)V (t) }/△t = −V (t)
′
/V (t)
Solving the above differential equation yields:
V (t) = V (0) exp
{
− ∫ t0 α(τ)dτ
}
= V (0) exp[−λ(t)t] (2.3)
where λ(t) =
∫ t
0 α(τ)dτ/t is the average relative lost rate of the viral load V (t). λ(t) can be
positive (if R < 1 ), zero (if R = 1 ), or negative (if R > 1 ). If λ(t) < 0, the decay rate λ(t)
at time t actually is a growth rate. Therefore, by including a time-varying decay rate function λ(t),
compared with equation (2.1), equation (2.3) is more flexible and can be applied to include the entire
follow-up data without need to arbitrarily truncate the data.
A unified model with a time-varying viral decay rate function can be expressed as:
y(t) = ln[V (t)] + ǫ = ln{V (0) exp[−λ(t)t]} + ǫ = β1 − λ(t)t+ ǫ (2.4)
where y(t) is the natural logarithm transformation of the number of HIV-1 RNA copies per mL
of plasma, ǫ is the measurement error, ln(V (0)) = β1 and is the macro-parameter for initial viral
load in natural log scale. In addition to the simplicity of this model’s structure, it also indicates that
the pattern of HIV decrease may be a physiologically structured, local non-equilibrium dynamic
interaction between HIV and immune activated cells after treatment initiation. Therefore, the overall
decay rate is the weighted average that is proportional to the local level of infection.
Among the different decay rate functions proposed in the literature, we select five representa-
tives as follow (Dagne and Huang, 2012; Grossman et al., 1999; Wu, 2004; Zhang and Wu, 2011),
I: λ(t) = β2 + β3t
II: λ(t) = β2 exp(−β3t) + β4
III: λ(t) = β2 exp(−β3t) + β4 + β5t
IV: λ(t) = β2 exp(−β3t) + β4 exp(−β5t)
V: λ(t) = v[w(t), hi(t)]
where the last one, λ(t) = v[w(t), hi(t)], is a nonparametric function.
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2.3. Bayesian mixed-effects models with skewed distribution
To account for the skewness observed in the data, the random errors in mixed-effects models can
be assumed to follow an SE distribution (see Section 1.4 in detail). The SE distribution is a family
of distributions that is not only mathematically tractable but also flexible in its possible shapes.
Because in the SE family, skew-normal (SN), normal and Student-t distribution are all a special
case of skew-t (ST) distribution, therefore, in this section, we present a general form of a mixed-
effects model with an ST distribution under the Bayesian approach. A general mixed-effects model
with an ST distribution can be expressed as:
yi = gi(ti,βi) + ei, ei
iid∼ STni,ν(0,Σ,∆),
βi = d(β, bi), bi
iid∼ N(0,Σb),
(2.5)
yi = (yi1, . . . , yini)
T with yij being the response value for the ith individual at the jth time (i =
1, 2, ..., n, j = 1, 2, ..., ni), gi(ti,βi) = (g(ti1,βi1), . . . , g(tini ,βini))T , ti = (ti1, . . . , tini)T ,
βi = (βi1, . . . ,βini)
T
, βij are individual-specific time-dependent parameter vectors and β is pop-
ulation parameter vector, g(·) and d(·) are linear or nonlinear known parametric functions, bi is
normal random-effect vector with Σb being an unstructured covariance matrix. The vector of ran-
dom errors ei = (ei1, . . . , eini)T follows a multivariate ST distribution with degrees of freedom
ν, within-subject covariance matrix Σ and we usually can assume Σ = σ2Ini , and unknown
ni × ni skewness diagonal matrix such that ∆ = diag(δi1, . . . , δini), skewness parameter vec-
tor δi = (δi1, . . . , δini)
T
. In particular, if δi1 = · · · = δini=ˆδ, then ∆ = δIni and δi = δ1ni ,
where 1ni = (1, . . . , 1)T , indicating that we are interested in skewness of overall data set.
Following discussion in Section 1.4.1, to implement an MCMC procedure to model (2.5), by
introducing one ni × 1 random vector wi, based on the stochastic representation, the model can be
hierarchically formulated as follows.
yi|bi,wi iid∼ tni,ni+ν(g(ti,βi) + δwi, wiσ2Ini),
wi
iid∼ tni,ni+ν(0, Ini)I(wi > 0),
bi
iid∼ N(0,Σb),
(2.6)
where wi = (ν + wTi wi)/(ν + ni), tni,ν(µ,A) denotes the ni-variate Student-t distribution with
parameters µ, A and degrees of freedom ν, I(w > 0) is an indicator function and w = |X0| with
X0 ∼ tni,ν(0, Ini). Note that the hierarchical model above under Bayesian framework will allow
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researchers to easily implement the methods using the freely available WinBUGS software (Lynn,
et al., 2000) and the computational effort for the model with an ST distribution is almost equivalent
to that of the model with a Student-t distribution.
The unknown population parameters in the model (2.5) are θ = {β, σ2,Σb, δ, ν}, and we as-
sume they are independent of one another. Under Bayesian framework, we also need to specify
prior distributions for unknown parameters as follows.
β ∼ N(β0,Λ), σ2 ∼ IG(ω1, ω2), Σb ∼ IW (Ω, v),
δ ∼ N(0, γ), ν ∼ Exp(ν0)I(ν > 2)
(2.7)
where the mutually independent Normal (N ), Inverse Gamma (IG), Exponential (Exp) and In-
verse Wishart (IW ) prior distributions are chosen to facilitate computations (Davidian and Gilti-
nan, 1995). The super-parameter matrices Λ and Ω can be assumed to be diagonal for convenient
implementation.
Let π(.) be a prior density function, so π(θ) = π(β)π(σ2)π(Σb)π(ν)π(δ). Denote the ob-
served data by D = {yi, i = 1, ..., n}, and f(·|·) as a conditional density function. Based on
Bayesian inference, the posterior density of θ is proportional to the observed data and prior distri-
bution as:
f(θ|D) ∝ {
n∏
i
∫
f(yi|bi,wi;β, σ2, ν, δ) f(wi|wi > 0) f(bi|Σb)dbi}π(θ) (2.8)
In general, the integral in (2.8) is of high dimension and does not have any closed form. An-
alytic approximations to the integral may not be sufficiently accurate. Therefore, it is prohibitive
to directly calculate the posterior distribution of θ based on the observed data. As an alternative,
MCMC procedures can be used to sample based on (2.8) by the Gibbs sampling along with the
Metropolis-Hastings (M-H) algorithm.
2.4. Application: AIDS clinical trial data
2.4.1. AIDS clinical trial data and specific models
We used two AIDS clinical trials to explore the best fit among the models with different time-varying
decay rate functions and different model random errors distribution assumption such as normal, SN,
Student-t and ST distribution. The first trial, A5055, is the focus. Further, we used data from another
clinical trial, A398 (Pfister et al., 2003), to validate the conclusions obtained from A5055.
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A5055 was a phase I/II, randomized, open-label, 24-week comparative study. It included 44
HIV-1 infected patients who failed their first protease inhibitor treatment. Subjects were randomly
assigned into one of the two arms. Subjects were scheduled for follow up visits at study day 0,
weeks 1, 2, and 4, and every 4 weeks thereafter through week 24. RNA viral load was measured
(copies/mL) in blood samples collected at study days 0, 7, 14, 28, 56, 84, 112, 140 and 168.
The nucleic acid sequence-based amplification assay (NASBA) was used to measure plasma HIV-1
RNA, with a low limit of quantification of 50 copies/mL. HIV-1 RNA measures below this limit
are not considered reliable, therefore we imputed such values as 25 copies/mL (Acosta et al., 2004;
Davidian and Giltinan, 1995). The mean, minimum and maximum values for the baseline viral
load were 6.09 × 103, 199 and 1.07 × 105 /mL, respectively. The average age of subjects was
37.8 years (SD=8.1) and approximately 80% of subjects had at least 8 measurements (including
the initial measurement). The mean and median number of days of follow-up were 155 and 168,
respectively.
A398 was a phase II trial that included 481 HIV-1 positive patients with prior exposure to
approved PIs and loss of virological suppression. All patients were assigned to receive routine ART.
Besides these medications, depending on the dose and type of PIs to which the patients previously
exposed, they were selectively randomly assigned into one of four arms. HIV-1 RNA levels were
measured at the time of entry into the study (day 0), at study weeks 2, 4, 8, 16, 24, 32, 40, and 48,
every 8 weeks thereafter, and at the time of confirmed virological failure. The mean, minimum and
maximum values for the baseline viral load were 2.76× 104, 260 and 1.32× 107/mL, respectively.
The low limit of quantification is 100 copies/mL and the HIV-1 RNA measures below this limit are
not considered reliable and 50 copies/mL was used instead. The average age of subjects was 40.1
years (SD=19) and approximately 74% subjects had at least 8 measurements (including the initial
measurement). The mean and median of follow-up is 168 and 144 days, respectively. We draw
two samples from A398 based on the method of simple random sampling without replacement, one
sample includes 44 subjects and the other includes 100 subjects. We also used all of the 481 subjects
in A398 in the model comparisons.
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Figure 2.3: Profiles of viral load in natural log scale for four randomly selected patients among
A5055 and A398, respectively
Figure 2.3 shows the measurements of viral load natural log scale for four randomly selected
patients from A5055 and two sample data sets from A398. We can see that viral load trajectories
vary widely and they are substantially different across individuals. To account for this time-varying
viral load change, we applied a mixed-effects model with a time-varying decay rate function, as
discussed in Section 2.2. In addition, we assumed the model errors followed an ST distribution in
order to make the model flexible in considering the skewness observed in the data. The exact day
of viral load measurement was used to compute study day in our analysis.
Under the general layout as model (2.4), corresponding to the five time-varying decay functions
presented in Section 2.2, the mixed-effects models can be expressed as follow.
Model I: Quadratic linear mixed-effects model:
yij = β1i − [β2i + β3itij]tij + eij
ei
iid∼ STni,v(0, σ2Ini , δIni)
β1i = β1 + b1i, β2i = β2 + b2i, β3i = β3 + b3i
(2.9)
where β = (β1, β2, β3)T and bi = (b1i, b2i, b3i)T
iid∼ N3(0,Σb).
Model II: Nonlinear mixed-effects model (uniexponential plus a constant):
yij = β1i − [β2i exp(−β3itij) + β4i]tij + eij
ei
iid∼ STni,v(0, σ2Ini , δIni)
β1i = β1 + b1i, β2i = β2 + b2i, β3i = β3 + b3i, β4i = β4 + b4i
(2.10)
where β = (β1, β2, β3, β4)T and bi = (b1i, b2i, b3i, b4i)T
iid∼ N4(0,Σb).
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Model III: Nonlinear mixed-effects model (uniexponential plus a linear function):
yij = β1i − [β2i exp(−β3itij) + β4i + β5itij]tij + eij
ei
iid∼ STni,v(0, σ2Ini , δIni)
β1i = β1 + b1i, β2i = β2 + b2i, β3i = β3 + b3i, β4i = β4 + b4i, β5i = β5 + b5i
(2.11)
where β = (β1, β2, β3, β4, β5)T and bi = (b1i, b2i, b3i, b4i, b5i)T
iid∼ N5(0,Σb).
Model IV: Nonlinear mixed-effects model (two uniexponential):
yij = β1i − [β2i exp(−β3itij) + β4i exp(−β5itij)]tij + eij
ei
iid∼ STni,v(0, σ2Ini , δIni)
β1i = β1 + b1i, β2i = β2 + b2i, β3i = β3 + b3i, β4i = β4 + b4i, β5i = β5 + b5i
(2.12)
where β = (β1, β2, β3, β4, β5)T and bi = (b1i, b2i, b3i, b4i, b5i)T
iid∼ N5(0,Σb).
Model V: Semiparametric mixed-effects model:
yij = β1i − v[w(tij), hi(tij)]tij + eij
where w(t) and hi(t) are unknown nonparametric smooth fixed-effects and random-effects func-
tions, respectively, and hi(t) are iid realizations of a zero-mean stochastic process. Model V is
a semiparametric mixed-effects model if w(t) and hi(t) are modeled non-parametrically such as
splines or local polynomials. There are several ways to approximate these nonparametric functions.
Following the similar approach as Shi et al.(1996), Rice and Wu (2001), Huang and Dagne (2010),
we used natural cubic basis function instead of smoothing splines (Ke and Wang, 2001; Wang 1998;
Zhang et al., 1998) or kernel methods (Wu and Zhang, 2002) for two reasons: this method is more
straightforward in application and we can select the bases by Akaike information criterion (AIC) or
the Bayesian information criterion (BIC) to balance the goodness-of-fit and model complexity. A
linear combination of base function can be expressed as:
w(t) ≈ wp(t) =
∑p−1
l=0 µlψl(t) = µpΨp(t)
T hi(t) ≈ hiq(t) =
∑q−1
l=0 ξilφl(t) = ξiqΦq(t)
T
where µp and ξiq (q ≤ p) are the unknown vectors of fixed and random coefficients, respectively.
We set ψ0 = φ0 ≡ 1 and took the same natural cubic splines in the approximations with p ≤ q,
based on the AIC and BIC values, selected the following:
w(tij) + hi(tij) ≈ µ0 + µ1ψ1(tij) + µ2ψ2(tij) + ξi0
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where p = 3 and q = 1. Model V, therefore, can be expressed as,
yij = β1i − [µ0 + µ1ψ1(tij) + µ2ψ2(tij) + ξi0]tij + eij
ei
iid∼ STni,v(0, σ2Ini , δIni)
β1i = β1 + b1i, β2i = µ0 + ξi0, β3 = µ1, β4 = µ2
(2.13)
where β = (β1, µ0, µ1, µ2)T and bi = (b1i, ξi0)T
iid∼ N2(0,Σb).
In each of the five models above, besides the ST distribution assumption, the model random
errors can also be assumed to follow other more specific distributions as normal, SN and Student-t.
We used several criteria to check the model fit by applying the models on the data mentioned above.
We first used deviance information criterion (DIC) (Spiegelhalter, 2002) to compare models.
DIC is a generalization of AIC that can be directly obtained from WinBUGS, it consists of two
components:
DIC = D(θ¯) + 2pD
pD = Eθ|y[−2 log p(y|θ)]− (−2 log p(y|θˆ(y)))
= Eθ|y[D(θ)]−D[Eθ|y(θ)] = D¯ −D(θ¯)
so, DIC = D¯ + pD
where D(θ) is deviance and defined as −2 log p(y|θ) and p(y|θ) is likelihood, D¯ is posterior mean
deviance which measures “goodness-of-fit”, the larger the value of D¯, the worse of the fit; pD is
the effective number of parameters that indicates “complexity”, the larger the value of pD, the more
complex is the model. Therefore, DIC = “goodness-of-fit” + “complexity”. Since D¯ will decrease as
the number of parameters in a model increases, the pD term compensates for this effect by favoring
models with fewer parameters. Unlike AIC and BIC that require calculating the likelihood at its
maximum over θ, which is not readily available from MCMC, DIC is easily calculated from the
samples generated by MCMC. Same as AIC and BIC, the smaller the value of DIC, the better of the
model fit. DIC is not intended for identification of the ‘correct’ model, but rather merely as a way
to compare a collection of alternative formulations.
Because model comparisons are critical for our study, besides DIC, we also compared the values
of expected predictive deviance (EPD) and residual sum of squares (RSS) that obtained from each
model. EPD is formulated byEPD = E{Σi,j(yrep,ij−yobs,ij)2}, where the predictive value yrep,ij
is a replicate of the observed yobs,ij and the expectation is taken over the posterior distribution of
the model parameters θ (Gelman et al., 2003). RSS is given by Σi,j(yobs,ij − yfitted,ij)2 and it is
a measure of the discrepancy between the data and an estimation model. The smaller the value of
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DIC, EPD and RSS, the better fit of the model to the data. Besides these statistical criteria, two
diagnostic plots, Quantile-Quantile plot (Q-Q plot) and plots of observed values vs. fitted values,
were also reported to give a visualized goodness-of-fit in the model comparisons.
We re-scaled the original time t (days) so that the time scale was between 0 and 1. We used
the entire follow-up data in all of the models. In the Bayesian inferential approach, we also need to
specify values of the hyper-parameters at the population level. Weakly informative prior distribu-
tions are taken for all the parameters: (i) for each component of fixed-effect vector of β, the prior
was assumed to follow independent normal distribution as N(0, 100); (ii) for the scale parameter
σ2, we assumed a limiting non-informative inverse gamma prior distribution as IG(0.01, 0.01),
therefore, the mean is 1 and variance is 100; (iii) the prior for the variance-covariance matrix for the
random-effect Σb was taken to be inverse Wishart distribution as IW (Ω, v), the degree of freedom,
v = 5, and Ω is diagonal matrix with diagonal elements being 0.01; (iv) for the skewness param-
eter δ, we chose normal distribution; (v) the degree of freedom ν followed truncated exponential
distribution with ν0 = 0.5
The MCMC sampler was implemented using WinBUGS software. The code for Model IV is
available in Appendix A. The posterior means and quantiles were drawn after the collecting the final
MCMC samples. We used one long chain. Convergence, which refers the algorithm has reached its
equilibrium target distribution, was closely watched by using the standard tools within WinBUGS
such as trace plots, the MC error and depicting the evolution of the ergodic means of a quantity over
the number of iterations. After an initial 100,000 burn-in iterations, every 50th MCMC sample was
retained from the next 200,000. Thus, we obtained 4,000 samples of targeted posterior distribution
of the unknown parameters for statistical inference.
2.4.2 Results
Step 1: in Section 2.4.2.1, we determine when the model errors are assumed to have an ST distribu-
tion, among the five models presented in Section 2.4.1, which one has the best fit. Step 2: in Section
2.4.2.2, because normal, SN and Student-t distribution are all a special case of an ST distribution,
focusing on the model selected from Step 1, we compare the results based on random errors with a
normal, SN and Student-t and ST distribution. The model comparisons are carried on A5055 data
and confirmed by A398 data. Step 3: Section 2.4.2.3 presents the results based on the best model
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selected. Step 4: Section 2.4.2.4 includes simulation study to validate the conclusions made from
Step 1 and Step 2.
Table 2.1: DIC, EPD and RSS among the five models, random errors are assumed to follow ST.
Data set Model I Model II Model III Model IV Model V
A5055: DIC 1192 401.1 669.2 21.7 1015.7
All subjects EPD 0.33 0.12 0.15 0.05 0.20
(n=44) RSS 59.2 20.7 27.1 8.4 35.3
A398: DIC 1239.4 1122.6 1162.9 576.9 1200.5
Sample 1 EPD 3.17 3.48 3.63 1.04 3.04
(n=44) RSS 396 436 454 134 381
A398: DIC 2264.9 1947.5 2855.3 1757.7 2204.5
Sample 2 EPD 0.44 0.51 3.45 0.33 0.39
(n=100) RSS 130.6 158.3 1083 99.4 116.7
A398: DIC 12900.6 10891.2 10763.4 8819.3 14217
All subjects EPD 1.49 1.42 1.31 0.93 1.84
(n=481) RSS 2665 2185 2059 1470 2703
2.4.2.1. Comparison of five models under an ST distribution
When we compare the models that have different components, we should not directly compare the
estimated parameters’ values because they have different meanings. However, because the models
were applied to the same HIV viral load data, we could use DIC, EPD and RSS to find out which
model had the best fit. The comparison results were shown in Table 2.1. Among all of the data
sets: A5055, the two randomly selected samples from A398 and A398 that includes all of the 481
subjects, Model IV constantly has the lowest DIC, EPD and RSS. For example, in A5055, DIC
value for Model IV is 21.7, while it is 1192, 401.1, 669.2, and 1015.7 in Models I, II, III and V,
respectively, which indicates Model IV is superior to the other models tested.
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2.4.2.2. Comparison of four distributions about random errors in the best fitted model -
Model IV
For Model IV, we further investigated how different distributions about random errors would affect
the model fit and DIC values are shown in Table 2.2 below. Among normal, Student-t, SN and
ST distribution, the model with either ST (A5055 and the two samples of A398) or SN (whole
A398) has the lowest DIC. Because SN has a simpler structure than ST, and the larger the degree of
freedom, the closer the Student-t distribution is to the normal distribution, it is not surprising to see
when the sample size is big (e.g. A398, n=481), SN has a smaller DIC value than ST.
Table 2.2: For Model IV, DIC values under different distribution assumptions.
Data set:
Distribution A5055 (n=44) A398 (n=44) A398 (n=100) A398 (n=481)
Normal 1133.3 961.4 2158.5 10222.0
SN 222.8 727.3 1937.2 7788.2
Student-t 1004.9 949.8 2144.3 8993.9
ST 21.7 576.9 1757.7 8819.3
We also calculated EPD and RSS, which provide the equivalent conclusions: for example, in
A5055 data (n=44), EPD is 0.05, 0.10, 2.19 and 2.29 for ST, SN, Student-t and normal, respec-
tively; in A398 data (n=481), EPD is 0.24, 0.93, 2.74 and 3.17 for ST, SN, Student-t and normal,
respectively;
We applied Model IV on A5055 to further compare the estimation results got from different
distribution assumptions. The population posterior mean (PM), the corresponding standard devi-
ation (SD) and 95% credible interval (CI) for fixed-effect parameters are presented in Table 2.3.
Table 2.3 shows: (i) except β5 based on the normal distribution assumption, all of the other es-
timates were significant since the 95% CIs don’t include zero; (ii) for variance σ2, the estimated
value based on the SN (0.05) and ST (0.01) models were much smaller than that based on the model
with normal (1.15) or Student-t (0.38) distribution; (iii) among all of the parameters estimated, the
related SD obtained from ST was the smallest; (iv) the estimates were similar between normal and
Student-t distribution model, but they were substantially different to those obtained from SN or ST
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model. For example, β2 based on normal or Student-t distribution was 34.67 and 38.10, respec-
tively, while it was 24.53 and 27.89 in SN and ST model, respectively; (v) the skewness parameter
δ was significantly positive in SN and ST, confirming the positive skewness of the viral load in the
natural logarithm transformed as observed in Figure 2.2; (vi) compared to the model with normal
or Student-t distribution assumption for random errors, the models with an SN or ST distribution
fit the data better. For example, in A5055, for DIC value, 11333.3 (normal) vs. 222.8 (SN), 1004.9
(Student-t) vs. 21.7 (ST), it indicates that consideration of a departure from normality will improve
the model fit.
Table 2.3: A summary of the estimated posterior values (based on A5055 data).
Model IV β1 β2 β3 β4 β5 σ2 δ DIC EPD RSS
Normal PM 8.30 34.67 5.95 6.77 0.38 1.15 – 1133.3 2.29 1133.3
LCI 7.81 26.86 4.01 2.65 -0.40 0.96 –
UCI 8.77 43.04 8.54 12.92 1.01 1.37 –
SD 0.26 4.15 1.26 2.52 0.35 0.11 –
SN PM 6.69 24.53 6.38 13.49 1.55 0.05 2.22 222.8 0.10 17.5
LCI 6.03 12.66 4.10 7.10 0.89 0.01 1.97
UCI 7.40 35.03 11.22 20.19 2.15 0.16 2.51
SD 0.35 5.69 1.72 3.85 0.37 0.04 0.14
Student-t PM 8.33 38.10 9.41 11.97 0.94 0.38 – 1004.9 2.19 420.8
LCI 7.84 30.31 7.34 8.99 0.66 0.28 –
UCI 8.83 46.61 11.64 15.59 1.24 0.50 –
SD 0.25 4.11 1.13 1.66 0.15 0.06 –
ST PM 7.18 27.89 7.19 13.69 1.73 0.01 1.17 21.7 0.05 8.4
LCI 6.66 21.53 6.34 11.72 1.55 0.00 0.99
UCI 7.67 33.93 8.63 16.22 1.98 0.04 1.34
SD 0.25 3.26 0.66 1.28 0.13 0.01 0.08
Note: LCI and UCI are lower limit and upper limit of 95% equal-tail credible interval, respectively
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Several diagnostic plots for goodness-of-fit are also applied. First, we randomly select three
subjects from A5055. The individual estimates of viral load trajectories are shown in Figure (2.4).
The following findings are observed: (i) the estimated individual trajectories got from SN and ST
fit the originally observed data much closer than those got from the model where the random errors
are assumed to be normal or Student-t; (ii) all of the 95% CI from the model with an SN or ST
distribution cover the observed viral load, where 21% and 19% of the 95% CI from normal and
Student-t, respectively, doesn’t include the observed values; (iii) the average SD got from ST is
the smallest, which is 0.15, while the mean of SD for the individual estimation got from SN, N
and Student-t is 0.22, 0.52 and 0.46, respectively. Note that the lack of smoothness in the SN and
ST Model estimates of individual trajectories is understandable since a random component wi was
incorporated in the expected function (see equation (2.6) for details) according to the stochastic
representation feature of the SN and ST distribution for “chasing the data” to this extent.
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Figure 2.4: Individual estimates of viral load trajectories for three randomly selected patients based
on normal, t, SN and ST distribution assumption in Model IV. The observed values are indicated by
diamond ♦
Second, we created two diagnostic plots: plots of the observed values versus the fitted values
(Figure 2.5) and Q-Q plot (Figure 2.6).
The findings of these two plots agree with that from DIC: the models with SN and ST distri-
bution provided better fit to the observed data than the ones with normal or Student-t distribution
assumption. Based on the results from DIC, EPD, RSS and the diagnostic plots, we conclude that
Model IV with the ST distribution assumption fits the data better than the other combinations be-
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tween a different time-varying viral decay rate functions and distribution assumption of random
errors.
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Figure 2.5: The observed values versus fitted values of ln(RNA) based on N, Student-t, SN or ST
distribution for random errors
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Figure 2.6: Q-Q plot
2.4.2.3. Simulation study
In order to validate the conclusions obtained from Steps 1 and 2 in Sections 2.4.2.1 and 2.4.2.2,
resampling method is used via a simple random sampling algorithm. Fifteen additional samples are
created from A398 and named as “A398-s1” to “A398-s15”, while each sample includes 44 subjects.
The validations are carried out in two scenarios. Firstly, we evaluate whether Model IV with the
ST distribution is the most appropriate among five models presented in Section 2.4.1. Secondly, we
assess whether Model IV with the ST distribution will provide better model fit in comparison of
Model IV with the N, Student-t and SN distribution assumptions.
Scenario one. Under the ST distribution assumption, Model I ∼ Model V are applied to the
fifteen samples created from A398 data set. The DIC values are shown in Table 2.4 and the related
Boxplots are presented in Figure 2.7. Model IV consistently has the smallest DIC value among
the five models. The average DIC in Model IV is 528.68, while it is 978.00, 859.38, 893.65 and
1051.66 in Model I, Model II, Model III and Model V, respectively. The boxplots shown in Figure
2.7 indicate that the median of DIC in Model IV is smaller than the values in the other four models,
while the medians of DIC are similar in Model I, II and III but smaller than the value in Model V.
Scenario two. After confirming that Model IV is the most appropriate model among the five
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models, we investigate among the fifteen samples, whether Model IV with the ST distribution pro-
vides better model fit than that with the N, Student-t and SN distributions. The DIC values are
shown in Table 2.5 and Figure 2.8. Among the four distribution assumptions, the median value
of DIC in Model IV with an ST distribution assumption is the lowest (641.47), followed by SN
(741.10), Student-t (856.60) and Normal (857.07).
In summary, we conclude that, based on the two resampling simulation studies, Model IV with
the ST distribution is the best model among the models with five time-varying decay rate functions
and/or four distributions. We will further report analysis results based on Model IV with the ST
distribution below.
Table 2.4: DIC values among the five models in the 15 samples from A398, random errors are
assumed to follow ST distribution.
Data set Model I Model II Model III Model IV Model V
A398-s1 1369.62 1335.26 1290.19 981.52 1379.38
A398-s2 931.63 348.82 509.20 171.86 1082.11
A398-s3 792.31 737.33 817.19 446.53 631.61
A398-s4 885.84 288.09 834.81 6.22 850.03
A398-s5 1199.30 1115.39 1132.25 778.70 1215.81
A398-s6 863.41 1105.55 1269.64 725.03 1208.31
A398-s7 844.77 636.58 700.77 557.90 906.25
A398-s8 1150.53 1059.46 1032.95 748.52 1155.85
A398-s9 1276.01 1102.07 1097.55 80.80 1273.38
A398-s10 860.40 954.13 871.74 779.33 1087.35
A398-s11 821.84 477.31 420.93 184.95 810.25
A398-s12 998.68 863.03 837.20 727.37 1002.01
A398-s13 1081.95 1189.50 1085.36 788.59 1317.84
A398-s14 1208.26 1010.11 920.54 788.37 1208.26
A398-s15 385.43 668.15 584.42 164.45 646.43
Mean 978.00 859.38 893.65 528.68 1051.66
SD 246.48 308.37 254.44 311.03 228.36
Median 931.63 908.58 882.7 641.47 1084.73
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Figure 2.8: Boxplot based on the DIC values from 15 samples in A398, in Model IV with different
distribution assumptions
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Table 2.5: For Model IV, among the 15 samples in A398, DIC values under different distribution
assumptions.
Statistics Normal SN Student-t ST
Mean 805.08 810.06 872.90 509.50
SD 240.54 355.03 115.70 313.82
Median 857.07 741.10 856.60 557.90
2.4.2.4. Results based on Model IV with an ST distribution
Based on Model IV with an ST distribution, the estimated population decay rate function for A5055
data is
λˆ(t) = 27.89 exp(−7.9t) + 13.69 exp(−1.73t).
Because the estimated λˆ(t) is always positive, the population viral load would always decrease in
this specific HIV/AIDS data set.
The individual time-varying decay rate function is given by,
λˆ(tij) = βˆi2 exp(−βˆi3tij) + βˆi4 exp(−βˆi5tij)
where the individual estimated decay rate λˆ(tij) is considered to be dependent on both subjects and
time. We found that the individual decay rate at initial treatment, λˆ(ti0), was positively correlated
with baseline viral load (Spearman correlation coefficient r = 0.769, p < 0.0001) and negatively
associated with baseline CD4 cell count (r = -0.447, p = 0.0025). Overall, the individual decay rate,
λˆ(tij), was positively associated with viral load (p < 0.0001) and negatively associated with CD4
cell count (p < 0.0001).
Because 30 ∼ 60% (Havlir et al., 2000) of patients eventually will have viral rebound, it is
important to have a model that can reasonably predict this type of treatment failure in the long term.
Following Wu et al.(2008), we defined rebound as, comparing with the HIV-1 viral load (natural
log transformed) from the previous measurement, if there was ≥ 1.15 increase at one time point
or ≥ 0.46 increase at two or more consecutive time points. In ACTG5055, there were 11 (26.2%)
subjects had rebound. There was no significant difference in the baseline viral load (natural log
(RNA)) between the rebound and no rebound group (median was 9.18 and 8.78, respectively, p =
40
0.8610), while the median of baseline CD4 cell count intended to be higher in the no rebound group
than that in the rebound group (285 vs. 253/mL, p = 0.1169).
The trend of the changes in decay rates during the treatment was different between the rebound
and no rebound group (Figure 2.9). For example, every individual decay rate was positive in the no
rebound group, while some individual decay rates in the rebound group became negative, especially
after the 3rd month of the treatment, which corresponding to the viral load rebound.
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Figure 2.9: Profile of viral load in ln scale and decay rate in rebound and no rebound group
Based on the results of Model IV under an ST distribution in A5055 data, we also find that:
(i) overall, the average value of individual decay rates, λˆ(tij), was bigger in the no rebound group
(14.97) than that in the rebound group (12.93); (ii) the initial individual decay rates, λˆ(ti1), were
significantly bigger in the no rebound group than that in the rebound group (mean is 53.16 and
40.95, respectively); (iii) λˆ(ti1) was significantly associated with the rebound status in the long
term (OR = 0.703, 95% CI is 0.580 – 0.853, p = 0.0003) and this association was still significant
even after controlling the baseline viral load and CD4 cell count (OR = 0.717, 95% CI is 0.588 –
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0.875, p = 0.0010). (iv) the average individual decay rate at the last visit (λˆ(tini)) among the no
rebound subjects was 4.67, while it was -2.28 in the rebound group which indicates the viral load
actually increasing instead of decreasing in this group. Among these findings, the most interesting
is the associated relationship between initial individual decay rate ( λˆ(ti0)) and the rebound status:
the results indicated that the odds of rebound decreased about 30% with each one unit increased in
the initial decay rate. This may be helpful for clinicians to predict the long term results based on the
information at early stage of the disease.
2.5. Conclusion and discussion
With an ST distribution assumption for model random errors to account skewness observed in viral
load responses, we compared five commonly used mixed-effects models in HIV dynamics via the
Bayesian approach. We also investigated the impact of the four distributions in the skew-elliptical
family on the model fit. The results indicate that with the ST distribution, there is potential gain of
efficiency and accuracy in estimating certain parameters when the normality assumption does not
apply to the data. The skew-elliptical modeling via the Bayesian approach proposed in this study
can be easily carried out via the WinBUGS package. Because the proposed model is quite general
in theory and accessible to the existing software, it will allow statisticians to apply this method in
other fields.
In any discussions of mathematical modeling of complex systems, it is important to point out
that, while complex models may be needed to provide accurate descriptions of the underlying dy-
namics, the models are most useful when they can be compared to clinical and/or experimental
data. In developing models for HIV infection and treatment, this requires a balance between com-
plexity and utility. After finding the best fitted model, we estimated the relationship between the
viral decay rate and some clinical important variables. Based on the results from the best fitted
model with an ST distribution assumption, we found the initial estimated decay rate was positively
correlated with the baseline viral load and negatively associated with baseline CD4 cell count. We
also found that, overall, the average decay rate was lower in the rebound than that in the no rebound
group. A more interesting finding is the significant association between the initial decay rate and
the rebound status in the long term, even after controlling for the baseline viral load and CD4 cell
count. This finding is clinically important because it may enable physicians to predict the long-term
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outcome based on the estimated decay rate at an early stage. Because we didn’t find such kinds of
associations based on the model with Student-t or normal distribution assumption, it is important to
consider non-normality into the modeling when the normality assumption cannot be satisfied even
after transformation.
Using the model with a time-varying decay rate function has some advantages over the bipha-
sical models. (i) In the biphasical models, the association between the first decay rate and baseline
viral load could be positive (Notermans et al., 1998; Wu et al., 2004) or negative (Wu et al., 1999);
no significant association was found between the rebound and the first decay rate either (Wu et al.,
2008); (ii) although the second decay rate in the biphasical models is supposed to be associated with
long-term treatment status such as rebound (Ding and Wu, 1999; Wu et al.,2005), no significant as-
sociation was found between the second decay rate and the viral replication in long term (Sedaghat
et al., 2008; Wu et al., 2003).
This chapter has some limitations. Usually, covariates are included in the mixed-effects models
to control within- and between-subject variation, and CD4 cell count is a commonly used covariate
in HIV dynamic models. However, in order to use the original proposed models in the comparisons,
we did not include any covariates such as CD4 cell count or demographic information. For the
viral load, the values below detection limit (BDL) are usually considered as inaccurate. Instead of
treating these values as censored, we computed them by half the value of the detectable level. The
issue of missing values is not considered in this study either.
This chapter compared commonly used HIV dynamic models and the estimation was through
Bayesian statistical inference. The mathematically modeling was extended from a normality as-
sumption and a general skew-elliptical distribution was used in order to account the skewness ob-
served in the data. New technologies were applied to facilitate the computation challenges related
to the complex nature of HIV/AIDS data. Furthermore, a more flexible distribution such as skew-
normal independent distribution, can be assumed; CD4 cell count, which can either be treated as a
covariate or an outcome in the HIV research, needs to be considered too, while the measurement
errors, skewness of CD4, and correlation with other factors such as CD8 are all worth to explore.
In conclusion, the skewness parameter in the model with SN or ST distribution is significantly
positive, which confirms the positive skewness observed in the viral load data even after natural log
transformed. The model fit is the best in the model with skewed (SN or ST) distribution. Because
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estimated parameters can be considerably different between the models with skewed distribution
and normal or Student-t distribution, it is important to account for skewness in the model when data
exhibits noticeable skewness. Different models may yield different conclusions about the relation-
ship between the decay rate with viral load, CD4 cell count and rebound status in HIV dynamics,
therefore, it is also critical to choose a reasonable model that can balance between complexity and
utility.
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3 Simultaneous Bayesian inference for linear, nonlinear and
semiparametric mixed-effects models with skew-normality and
measurement errors in covariates
Disclaimer
This chapter has already been published as: Huang, Yangxin; Chen, Ren; and Dagne, Getachew
(2011) “Simultaneous Bayesian Inference for Linear, Nonlinear and Semiparametric Mixed-Effects
Models with Skew-Normality and Measurement Errors in Covariates”. The International Journal
of Biostatistics: Vol. 7 : Iss. 1, Article 8. The permission of including it in the dissertation is in
the Appendix D. Except the section numbers and question numbers changing in order to make the
chapters labeling constant, all of the remaining contents in Chapter 3 are in the original format.
Abstract
In recent years various mixed-effects models have been suggested for estimating viral decay
rates in HIV viral dynamic models for complex longitudinal data. Among those models are lin-
ear mixed-effects (LME), nonlinear mixed-effects (NLME), and semiparametric nonlinear mixed-
effects (SNLME) models. However, a critical question is whether these models produce coherent
estimates of viral decay rates, and if not, which model is appropriate and should be used in practice.
In addition, one often assumes that model random errors are normally distributed, but the normality
assumption may be unrealistic, particularly, if the data exhibit skewness. Moreover, some covariates
such as CD4 cell count may be often measured with substantial errors. This paper addresses these
issues simultaneously by jointly modeling the response variable with skewness and a covariate pro-
cess with measurement errors using a Bayesian approach to investigate how estimated parameters
are changed or different under these three models. A real data set from an AIDS clinical trial study
was used to illustrate the proposed models and methods. It was found that there was a significant
incongruity in the estimated decay rates in viral loads based on the three mixed-effects models,
suggesting that the decay rates estimated by using Bayesian LME or NLME joint models should be
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interpreted differently from those estimated by using Bayesian SNLME joint models. The findings
also suggest that the Bayesian SNLME joint model is preferred to other models because an arbitrary
data truncation is not necessary; and it is also shown that the models with a skew-normal distribution
and/or measurement errors in covariate may achieve reliable results when the data exhibit skewness.
3.1. Introduction
Modeling of HIV dynamics in AIDS research has greatly improved our understanding of the patho-
genesis of HIV-1 infection and guided for the treatment of AIDS patients and evaluation of an-
tiretroviral (ARV) therapies (Perelson, 1997; Wu and Ding, 1999; Wu et al., 2005). Such models
often incorporate repeated measures over a period of treatment to assess rates of changes in viral
load (number of HIV RNA copies in plasma). Recent research indicates that the first-phase de-
cay rate of viral response to treatment is a potentially useful biomarker for ARV potency (Ding
and Wu, 1999). Even though various statistical modeling and analysis methods have been applied
for estimating the parameters of HIV dynamics, such as, linear and nonlinear regression (Perelson,
1997), linear mixed-effects (LME) and nonlinear mixed-effects (NLME) modeling approach (Wu
and Ding, 1999; Wu, et al., 1998, 2004; Wu, 2004), nonparametric NLME modeling approach (Liu
and Wu, 2007; Wu and Zhang, 2002; Wu, et al., 2004), joint model approach via Monte Carlo EM
algorithm (Liu and Wu, 2007; Wu, 2002; Wu, 2004) and Bayesian NLME modeling approach via
Markov chain Monte Carlo (MCMC) procedure (Huang et al., 2006; Huang and Dagne, 2010), it is
not clear which model should be used to estimate the first-phase decay rate. More importantly, in
all of these models at least one of the following three important issues standout.
Firstly, the common assumption of distributions for (within-subject) random error is normal in
those statistical models. This assumption may lack the robustness against departures from normal-
ity and/or outliers as discussed by Verbeke and Lesaffre (1996), and may also lead to misleading
results (Verbeke and Lesaffre, 1996; Ghosh et al., 2007). Very often in AIDS studies, the viro-
logic responses exhibit skewness. For example, Figure 3.1 displays the histograms of repeated viral
load (in natural log scale) and CD4 cell count measurements for 44 subjects enrolled in the AIDS
clinical trial study–A5055 (Acosta et al., 2004). It seems that for these data sets to be analyzed in
this paper, the viral load responses are highly skewed even after natural log-transformation. Thus,
a normality assumption is not quite realistic and may be too restrictive to provide an accurate rep-
46
resentation of the structure of the data. One way to incorporate skewness is to use a skew-normal
(SN) distribution for (within-subject) random errors. Secondly, the mixed-effects models have been
used in the previous studies to account for both between-subject and within-subject variations in
viral load measurements which are associated with covariates including CD4 cell count. However,
the covariates such as CD4 cell count which were considered in those studies are often measured
with substantial errors and highly skewed as shown in Figure 3.1(down panel). Thirdly, a major
challenge with these modeling approaches is the associated intensive computation burden in the
inference, and in some cases it can even be computationally infeasible. Particularly, for nonlinear
longitudinal models in the presence of measurement errors in covariates, the computational problem
becomes much worse. In addition, there may exist the problem of non-convergence of these algo-
rithms under the framework of likelihood estimation. To the best of our knowledge, there is little
literature on simultaneously addressing measurement errors in covariates and an SN distribution for
random errors to compare performance of the various mixed-effects models under the framework of
Bayesian mixed-effects modeling approach. This article provides a unified approach to investigate
SN Bayesian mixed-effects models with covariate measurement errors.
In this paper, the main focus is to provide a comprehensive comparison of three mixed-effects
models (LME, NLME and semiparametric NLME) with an SN distribution and measurement errors
in covariates for estimated viral decay rates in viral dynamic models. We consider a multivariate
SN distribution introduced by Sahu et al.(2003) which is suitable for a Bayesian inference since it
is built using conditional method and is defined in Section 1.4. The rest of the paper is organized
as follows. Section 3.2 presents a general modeling approach for SN Bayesian semiparametric
nonlinear mixed-effects (SN-BSNLME) joint models which include three specific models as special
cases to be discussed in Section 3.3. We describe data from an AIDS clinical study that motivated
this research, discuss the specific models for HIV dynamics and reports the results obtained by
using the three different methods or models In Section 3.3. Finally, the paper concludes with some
discussions in Section 3.4.
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Figure 3.1: The histograms of viral load (in ln scale) and standardized CD4 cell count measured
from day 0 to day 35 [Set (a): data cut at truncation day 35], day 84 [Set (b): data cut at truncation
day 84] and the end of study period [Set (c): complete data] for 44 patients in an AIDS clinical trial
study.
3.2. Bayesian inference on joint models with skew-normal distributions
3.2.1. Measurement error models with a skew-normal distribution
This section will briefly discuss measurement error joint models with a skew-normal distribution.
Various covariate models were investigated in the literature (Carroll et al., 2006; Higgins et al., 1997;
Liu and Wu, 2007; Wu, 2002). However, the fundamental assumption of distributions for measure-
ment random errors is normal in these statistical covariate models and this assumption may lack
the robustness against departures from normality and/or may violate the agreement with observed
data. Thus statistical inference and analysis with normal assumption may lead to misleading results.
In this paper, we extend the covariate models to have a skew-normal distribution for measurement
errors. For simplicity, we consider a single time-varying covariate. Let zik be the observed covari-
ate value for individual i at time sik (i = 1, . . . n; k = 1, . . . ,mi). Note that for each individual,
we allow the covariate measurement times sik to differ from the response measurement times tij
(j = 1, . . . , ni). In the presence of measurement errors in covariate, we need to model the covariate
process. We consider the following LME model with an SN distribution
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zik = u
T
ikα+ v
T
ikai + ǫik (≡ z∗ik + ǫik), ǫi iid ∼ SNmi
(
0, τ2Imi ,∆ǫ
)
, (3.1)
where zi = (zi1, . . . , zimi)T with zik being the covariate value for individual i at time sik, uik
and vik are l × 1 design vectors, α = (α1, . . . , αl)T and ai = (ai1, . . . , ail)T are unknown pop-
ulation (fixed-effects) and individual-specific (random-effects) parameter vectors, respectively, and
ǫi = (ǫi1, . . . , ǫimi)
T is a multivariate skew-normal distribution with ǫik being the measurement
error for individual i at time sik, τ2 is the unknown within-individual variance. The mi × mi
skewness diagonal matrix ∆ǫ = diag(δǫi1 , . . . , δǫimi ) and mi × 1 skewness parameter vector
δǫi = (δǫi1 , . . . , δǫimi )
T
. In particular, if δǫi1 = · · · = δǫimi =ˆδǫ, then ∆ǫ = δǫImi and δǫi = δǫ1mi
with 1mi = (1, . . . , 1)T ; this indicates that we are interested in skewness of overall data set
which is the case to be used in real data analysis in the next section. z∗i = (z∗i1, . . . , z∗imi)
T and
z∗ik = u
T
ikα+v
T
ikai may be viewed as the true (but unobservable) covariate values at time sik under
normal distribution of model errors in which case skewness parameter δǫik = 0. We assume that
ai iid ∼ Nl(0,Σa), where Σa is the unrestricted covariance matrix. Note that the model (3.1)
may be interpreted as a skew-normal (SN) covariate measurement error model which incorporates
the correlation of the repeated measurements on each individual.
3.2.2. Skew-normal Bayesian semiparametric nonlinear mixed-effects joint models
In this section, we present the joint models and methods in general forms, illustrating that our meth-
ods may be applicable in other applications. Denote the number of subjects by n and the number of
measurements on the ith subject by ni. For the response process, we consider a general semipara-
metric NLME (SNLME) model which is similar to Wu and Zhang (2002) but incorporates possibly
mis-measured time-varying covariates and model random errors with a skew-normal distribution.
yij = g(tij ,β
†
ij, φ(tij)) + eij, ei iid ∼ SNni
(
0, σ2Ini ,∆
)
,
β
†
ij = d
†[z∗ij ,β
†, b†i ], b
†
i iid ∼ Ns3(0,Σ†b),
φ(tij) = v[w(tij), hi(tij)], i = 1, 2, . . . , n; j = 1, 2, . . . , ni,
(3.2)
where yi = (yi1, . . . , yini)T with yij being the response value for individual i at tij , g(·), d†(·)
and v(·) are known parametric functions, w(t) and hi(t) are unknown nonparametric smooth
fixed-effects and random-effects functions, respectively, hi(t) are iid realizations of a zero-mean
stochastic process, β†ij are s1 × 1 individual-specific time-dependent parameter vectors, β† are
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s2 × 1 population parameter vectors (s2 ≥ s1), σ2 is the unknown within-subject variation,
ei = (ei1, . . . , eini)
T is the vector of random errors; b†i are s3 × 1 vector of random-effects
(s3 ≤ s1) and Σ†b is the unrestricted covariance matrix. The ni × ni skewness diagonal matrix
∆ = diag(δei1 , . . . , δeini ) and the ni × 1 skewness parameter vector δei = (δei1 , . . . , δeini )T . In
particular, if δei1 = · · · = δeini =ˆδe, then ∆ = δeIni and δei = δe1ni . In the model (3.2), we
assume that the individual-specific parameters β†ij depend on the true (but unobservable) covariate
z∗ij rather than the observed covariate zij , which may be measured with errors.
Semiparametric NLME model (3.2) is more flexible than parametric NLME models. It reverts
to a parametric NLME model when the nonparametric parts w(t) and hi(t) are constants. To fit
model (3.2), we apply the regression spline method. The working principle is briefly described
as follows and more details can be found in Wu and Zhang (2002). The main idea of regres-
sion spline is to approximate w(t) and hi(t) by using a linear combination of spline basis func-
tions. For instance, w(t) and hi(t) can be approximated by a linear combination of basis functions
Ψp(t) = {ψ0(t), ψ1(t), ..., ψp−1(t)}T andΦq(t) = {φ0(t), φ1(t), ..., φq−1(t)}T , respectively. That
is,
w(t) ≈ wp(t) =
p−1∑
l=0
µlψl(t) = µpΨp(t)
T , hi(t) ≈ hiq(t) =
q−1∑
l=0
ξilφl(t) = ξiqΦq(t)
T , (3.3)
where µp and ξiq (q ≤ p) are the unknown vectors of fixed and random coefficients, respectively.
Based on the assumption of hi(t), we can regard ξiq as iid realizations of a zero-mean random
vector. For our model, we consider natural cubic spline bases with the percentile-based knots.
To select an optimal degree of regression spline and numbers of knots, i.e., optimal sizes of p
and q, the Akaike information criterion (AIC) or the Bayesian information criterion (BIC) is often
applied (Davidian and Giltinan, 1995; Wu and Zhang, 2002). Substituting w(t) and hi(t) by their
approximations wp(t) and hiq(t), we can approximate model (3.2) in a compact way as follows.
yij = g
(
tij,d
†[z∗ij ,β
†, b†i ], v[Ψp(tij)
Tµp,Φq(tij)
T ξiq]
)
+ eij ≡ g
(
tij ,d[z
∗
ij ,β, bi]
)
+ eij (3.4)
where β = (β†T ,µTp )T and bi = (b
†T
i , ξ
T
iq)
T are the vectors of fixed-effects and random-effects,
respectively, and d(·) is a known but possible nonlinear function. By doing so, the randomness
of the nonparametric mixed-effects is transferred to the randomness of the associated coefficients,
whereas the nonparametric feature is represented by the basis functions. Thus, for given Ψp(t) and
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Φq(t), we approximate the SN semiparametric NLME model (3.2) by the following SN parametric
NLME model.
yi = gi(tij ,βij) + ei, ei iid ∼ SNni
(
0, σ2Ini ,∆
)
,
βij = d[z
∗
ij ,β, bi], bi iid ∼ Ns4(0,Σb),
(3.5)
where s4 = s3 + q, gi(tij ,βij) = (g(ti1,βi1), . . . , g(tini ,βini))
T with g(·) being a known linear
or nonlinear function, and Σb is an unstructured covariance matrix.
Under Bayesian framework, we still need to specify prior distributions for unknown parameters
in the models (3.1) and (3.5) as follows.
α ∼ Nr(α0,Λ1), τ2 ∼ IG(ω1, ω2), Σa ∼ IW (Ω1, ν1), δǫi ∼ Nmi(0,Γ1),
β ∼ Ns5(β0,Λ2), σ2 ∼ IG(ω3, ω4), Σb ∼ IW (Ω2, ν2), δei ∼ Nni(0,Γ2),
(3.6)
where s5 = s2+p, the mutually independent Inverse Gamma (IG), Normal (N ) and Inverse Wishart
(IW ) prior distributions are chosen to facilitate computations (Davidian and Giltinan, 1995). The
super-parameter matricesΛ1,Λ2,Ω1,Ω2, Γ1 and Γ2 can be assumed to be diagonal for convenient
implementation.
We assume that ei, ǫi, bi and ai are independent of each other. Following Sahu et al.(2003) and
properties of skew-normal distribution, it can be shown that zi and yi in the models (3.1) and (3.5)
follow the following distributions
yi|ai, bi,wei ∼ Nni
(
gi + δewei , σ
2Ini
)
, wei ∼ Nni(0, Ini)I(wei > 0),
zi|ai,wǫi ∼ Nmi
(
z∗i + δǫwǫi, τ
2Imi
)
, wǫi ∼ Nmi(0, Imi)I(wǫi > 0),
(3.7)
where I(wk > 0) is an indicator function and wk = |ξ| with ξ ∼ Nk(0, Ik).
Let θ = {α,β, τ2, σ2,Σa,Σb, δǫi , δei ; i = 1, . . . , n} be the collection of unknown parameters
in the models (3.1) and (3.5), and f(·|·) and π(·) be a conditional density function and a prior
density function, respectively. Denote the observed data byD = (( yi, zi), i = 1, ..., n ). We assume
that α,β, τ2, σ2,Σa,Σb, δǫi , δei (i = 1, . . . , n) are independent of each other, and thus we have
π(θ) = π(α)π(β)π(τ2)π(σ2)π(Σa)π(Σb)
∏
i π(δǫi)π(δei). After we specify the models for the
observed data and the prior distributions for the unknown model parameters, we can make statistical
inference for the parameters based on their posterior distributions under Bayesian framework. The
joint posterior density of θ based on the observed data can be given by
f(θ|D) ∝ {
n∏
i
∫ ∫
f(yi|ai, bi,wei ;α,β, σ2, δei) f(wei |wei > 0)×
f(zi|ai,wǫi ;α, τ2, δǫi)f(wǫi |wǫi > 0) f(ai|Σa) f(bi|Σb)daidbi}π(θ).
(3.8)
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In general, the integrals in (3.8) are of high dimension and do not have closed form. Analytic
approximations to the integrals may not be sufficient accurate. Therefore, it is prohibitive to directly
calculate the posterior distribution of θ based on the observed data. As an alternative, MCMC
procedures can be used to sample based on (3.8) using the Gibbs sampler along with the Metropolis-
Hastings (M-H) algorithm. The above representations based on the models are useful as it allows to
implement easily using the WinBUGS codes (Lunn et al., 2000).
3.3. Analysis of AIDS clinical data
3.3.1. Data and models
We illustrate our methods using a real AIDS clinical data. The study consists of 44 HIV-infected pa-
tients who were treated with a potent ARV regimen. Viral load, CD4 cell count and other variables
were repeatedly measured over a period of 24 weeks. RNA viral load was measured in copies/mL
at study days 0, 7, 14, 28, 56, 84, 112, 140 and 168 of follow-up. The nucleic acid sequence-
based amplification assay (NASBA) was used to measure plasma HIV-1 RNA, with a lower limit
of quantification, 50 copies/mL. the HIV-1 RNA measures below this limit are not considered reli-
able, therefore we simply imputed such values as 25 copies/mL (Acosta et al., 2004; Davidian and
Giltinan, 1995). Covariates such as CD4 cell count including associated baseline data were also
measured throughout the study on similar schemes. Figure 3.2 shows the measurements of viral
load in natural log scale and CD4 cell count for the three randomly selected patients. Both viral
load and CD4 cell count trajectories exhibit distinctive and important patterns throughout the time
course. We can see that the rate change in viral load appears to vary substantially across patients,
reflecting both biological variation and systematic associations with subject-level covariates.
The baseline value of HIV-1 RNA in plasma (ln scale) ranged from 5.296 to 11.582 with mean
8.715 and standard deviation 1.531. As is evident from Figure 3.3(c), RNA levels varied widely
during the early treatment stage. For some patients, the RNA level decreased rapidly with treat-
ment (described as the first-phase decay rate); for others it decreased slowly. Studying the relation
between baseline RNA and the first-phase decay rate will provide useful information for clinical
decision-making and treatment individualization. The first-phase decay rate indicates the potency
of ARV therapies (Ding and Wu, 1999). If we know the potency of a treatment at an earlier stage,
we may be able to avoid the less potent regimens for a particular patient. This will help clinicians
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Figure 3.2: Profiles of viral load (response) in natural log scale and CD4 cell count (covariate) for
three randomly selected patients. The horizontal line is below the detectable level of viral load
(3.91=log(50)) and the two vertical lines represent truncation days 35 and 84, respectively.
to select a treatment for their patients. Although the patients may receive the same treatment, there
may still exist the difference in the potency for different patients with the same regimen. This is be-
cause the patients may absorb the drug differently, and patients’ immune systems and other factors
related to response of the drugs may be different.
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Figure 3.3: Profiles of viral load in ln scale from an AIDS clinical trial study. Change in HIV-1
load, measured from RNA levels in plasma, with time during treatment from day 0 to (a) day 35,
(b) day 84 and (c) the end of study period.
Viral dynamic models can be formulated through a system of ordinary differential equations
(ODE) (Huang et al., 2006; Wu et al., 1998; Wu and Ding, 1999). In practice, some investigators
have used a LME model simplified from an ODE system to fit viral dynamic data from the very
early time period such as displayed in Figure 3.3(a). Their response model can be described by the
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following linear model
y(t) = ln{V (t)} = β1 − β2t+ e(t) (3.9)
where y(t) is the natural logarithm of the number of HIV-1 RNA copies per mL of plasma, e(t)
is the measurement error, β2 is the first-phase viral decay rate which may represent the minimum
turnover rate of productively infected cells (Perelson et al., 1997) and β1 is macro-parameter with
exp(β1) being the baseline viral load at time t = 0.
Due to the limitations of current assays, only two infected cell compartments can be identified
which are believed to produce a biphasic viral decay (Perelson et al., 1997). Based on biological
and clinical arguments, an effective model used to estimate viral dynamic parameters is the biphasic
model approximated from a compartmental analysis-based an ODE system (Perelson et al., 1997;
Wu and Ding, 1999). This model plays an important role in modeling HIV dynamics and has
demonstrated promise in studying HIV response process. The model is described as follows.
y(t) = ln{V (t)} = ln {exp[β1 − β2t] + exp[β3 − β4t]}+ e(t) (3.10)
where β4 is the second-phase viral decay rate which may represent the minimum turnover rate of
latently or long-lived infected cells (Perelson et al., 1997) and exp(β1) + exp(β3) is the baseline
viral load at time t = 0. It is generally assumed that β2 > β4, which assures that the model is
identifiable and is appropriate for empirical studies. It is of particular interest to estimate the viral
decay rates β2 and β4 because they quantify the antiviral effect and hence can be used to assess
the efficacy of the antiviral treatments (Ding and Wu, 1999). In estimating these decay rates, only
the early segment of the viral load trajectory data (for example, data shown in Figure 3.3(b)) can
be used (Perelson et al., 1997; Wu and Ding, 1999), because the viral load trajectory may have a
different shape in later stages (see Figure 3.3(c)).
Although the models (3.9) and (3.10) are widely used in HIV dynamic studies and have shown
promise, there are some concerns. For example, when different models give different conclusions,
how do we know which is correct and should be used? In our analysis of the clinical data shown
above, the models (3.9) and (3.10) produce incongruous estimates of viral decay rates of β2 and
provide conflicting results on their correlations with baseline viral load: one indicates a strongly
positive correlation between baseline HIV-1 RNA levels and the first-phase decay rate and the other
indicates that these two factors are negatively correlated. In addition, both models are applied to
the early segment of the viral load data. That means one has to cut the data at some arbitrary time
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point. It is not obvious what time point should be the cut-point or whether we should use different
cut-points. To avoid these problems, a semiparametric biexponential model was proposed as follows
(Wu and Zhang, 2002).
y(t) = ln{V (t)} = ln {exp[β1 − β2t] + exp[β3 − β4(t)t]}+ e(t) (3.11)
where the second-phase decay rate β4(t) is a smooth unknown function. Intuitively, model (3.11) is
more reasonable because it assumes that the viral decay rate in the second-phase can vary with time
as a result of drug resistance, pharmacokinetics, medication adherence and other relevant clinical
factors likely to affect changes in the viral load during the late stage of treatment. Therefore, all
data obtained during ARV treatment can be used by fitting model (3.11). We also assume that
β2 > β4(t) for all time in order to guarantee that there is the first phase of curve decay. This
is a semiparametric model because of the mechanistic structure (two-exponential) with constant
parameters (β1, β2, β3) and a time-varying parameter (β4(t)) to capture the time-varying effects
of the treatment and over a longer period. This semiparametric model preserves compartmental
mechanistic interpretation (Perelson et al., 1997; Wu and Ding, 1999) of the original parametric
model under the biexponential form. In particular, the turnover rate of productively infected cells,
β2, can still be estimated. Actually, by including long-term viral load data, the estimate of β2 may
be more accurate and reasonable compared with those obtained in previous studies (Perelson et al.,
1997; Wu and Ding, 1999) after excluding long-term viral load data for modeling and analysis by
some ad hoc rules (that is, the screening and inclusion of viral load data are quite arbitrary). In
the mean time, this model enjoys the flexibility of a semiparametric function for the second-phase
decay rate β4(t). The estimate of β4(t) provides not only an approximate turnover rate over time
of long-lived/latently infected cells at the early stage of treatment as the standard parametric model
does, but also more importantly describes how it may change over a long treatment period as driven
by, presumably, drug resistance, non-compliance and other clinical determinants. Most importantly,
the semiparametric model is capable of modeling long-term viral load data of which the trajectory
may vary substantially among different patients (Wu and Zhang, 2002). It is noted that the three
different models are applied to different segments of the viral dynamic data. Therefore, the standard
goodness-of-fit or model selection methods cannot be used to identify the appropriate model.
To characterize skewness appeared often in viral loads and CD4 cell count, we will develop
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SN Bayesian mixed-effects joint models in conjunction with the three dynamic response models
and LME covariate model. To model the covariate CD4 process, we consider empirical polynomial
LME models and choose the best model (3.1) with quadratic (l = 3) based on AIC/BIC model
selection criteria as suggested by Liu and Wu (2007) and Wu (2002). We thus adapted the quadratic
polynomial as the SN covariate model (3.1) with uik = vik = (1, sik, s2ik)T for the CD4 trajectory
as follows.
zik = z
∗
ik + ǫik, ǫi ∼ SNmi
(
0, τ2Imi , δǫImi
)
, (3.12)
where z∗ik = (α1 + ai1) + (α2 + ai2)sik + (α3 + ai3)s2ik, α = (α1, α2, α3)T is population (fixed-
effects) parameter vector, and ai = (ai1, ai2, ai3)T is individual-specific (random-effects) vector
with normal distribution N3(0,Σa). Special cases of the model (3.2), which are offered to jointly
model HIV dynamics in the presence of CD4 covariate process with measurement errors described
in the model (3.12), are discussed below.
Model I: SN Bayesian semiparametric nonlinear mixed-effects (SN-BSNLME) joint model (3.5)
based on the semiparametric biexponential model (3.11) in conjunction with the SN covariate model
(3.12) along with specified prior distributions (3.6) can be expressed as
yij = ln {exp[βi1 − βi2tij] + exp[βi3 − βij4(tij)tij ]}+ eij , ei ∼ SNni
(
0, σ2Ini , δeIni
)
,
βi1 = β1 + bi1, βi2 = β2 + bi2, βi3 = β3 + bi3, βij4(tij) = β4 + β5z
∗
ij + w(tij) + hi(tij),
(3.13)
where β = (β1, β2, β3, β4, β5,µTp )T , bi = (bi1, bi2, bi3, ξTiq)T ∼ N3+q(0,Σb); see equation (3.16)
below for detailed specification about µp and ξiq. We can see that the SN-BSNLME joint model
above reverts to an SN Bayesian nonlinear mixed-effects (SN-BNLME) models when the nonpara-
metric parts w(t) and hi(t) become constants. More specifically, the SN-BNLME model reduces
to an SN Bayesian linear mixed-effects (SN-BLME) model when the response function is linear.
Thus, we next present the following two simplified mixed-effects models.
Model II: SN Bayesian Nonlinear Mixed-Effects (SN-BNLME) joint model based on the biexpo-
nential model (3.10) in conjunction with the SN covariate model (3.12) can be expressed as
yij = ln {exp[βi1 − βi2tij] + exp[βi3 − βij4tij ]}+ eij , ei ∼ SNni
(
0, σ2Ini , δeIni
)
,
βi1 = β1 + bi1, βi2 = β2 + bi2, βi3 = β3 + bi3, βij4 = β4 + β5z
∗
ij + bi4,
(3.14)
where β = (β1, β2, β3, β4, β5)T and bi = (bi1, bi2, bi3, bi4)T ∼ N4(0,Σb).
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Model III: SN Bayesian Linear Mixed-Effects (SN-BLME) model based on the linear model (3.9)
can be written as
yij = βi1 − βi2tij + eij, ei ∼ SNni
(
0, σ2Ini , δeIni
)
,
βi1 = β1 + bi1, βi2 = β2 + bi2,
(3.15)
where β = (β1, β2)T and bi = (bi1, bi2)T ∼ N2(0,Σb).
3.3.2. Results of analysis
In this section, we report the results of our analysis of the three data sets (mentioned in Figure 3.3)
using SN-BLME, SN-BNLME and SN-BSNLME joint models, respectively. A natural log transfor-
mation for viral load data was used in the analysis in order to stabilize the variation of measurement
error and speed up estimation algorithm. To avoid very small (large) estimates which may be un-
stable, we standardize the time-varying covariate CD4 cell count (each CD4 value is subtracted by
mean 375.46 and divided by standard deviation 228.57) and rescale the original time t (in days)
so that the time scale is between 0 and 1. To fit the SN-BLME model and the SN-BNLME joint
model, we included only the viral load data from day 0 to day 35 (Figure 3.3(a)) and day 0 to day
84 (Figure 3.3(b)), respectively, because the SN-BLME model could only be used to fit linear tra-
jectories of viral load and the SN-BNLME assumptions might be violated after long-term treatment
if there are rebounds of viral load (i.e., we excluded the significant rebound data from the analysis).
In fitting the SN-BSNLME joint model, we use all viral load data shown in Figure 3.3(c) and em-
ploy the linear combinations of natural cubic splines with percentile-based knots to approximate the
nonparametric functions w(t) and hi(t). Following studies in (Liu and Wu, 2007; Wu and Zhang,
2002), we set ψ0(t) = φ0(t) ≡ 1 and take the same natural cubic splines in the approximations
(3.3) with q ≤ p. The values of p and q are determined based on the AIC/BIC which suggest the
following function for βij4(tij) with p = 3 and q = 1 in the model (3.13).
βij4(tij) ≈ β4 + β5z∗ij + µ0ψ0(tij) + µ1ψ1(tij) + µ2ψ2(tij) + ξi0. (3.16)
To carry out Bayesian inference, we need to specify the values of the hyper-parameters in the
prior distributions. In Bayesian approach, we only need to specify the priors at the population level.
We take weakly informative prior distributions for all the parameters. In particular, (i) fixed-effects
were taken to be independent normal distribution N(0, 100) for each component of the population
parameter vectors α and β. (ii) For the scale parameters σ2 and τ2 we assume a limiting non-
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informative inverse gamma prior distribution, IG(0.01, 0.01) so that the distribution has mean 1
and variance 100. (iii) The priors for the variance-covariance matrices of the random-effects Σa
and Σb are taken to be inverse Wishart distributions IW (Ω1, ν1) and IW (Ω2, ν2), where degree
of freedom ν1 = ν2 = 5, and Ω1 and Ω2 are diagonal matrices with diagonal elements being 0.01.
(iv) For each of the skewness parameters δe and δǫ, we choose independent normal distribution
N(0, 100), where we specify that δei = δe1ni and δǫi = δǫ1mi to indicate that we are interested in
skewness of both overall viral load data and overall CD4 cell count data.
The MCMC sampler was implemented using WinBUGS software (Lunn et al., 2000), and the
program codes are available in Appendix B. In particular, the MCMC scheme for drawing sam-
ples from the posterior distributions of all parameters in the both response and covariate mod-
els is obtained by iterating between the following two steps: (i) Gibbs sampler is used to update
α,β, τ2, σ2,Σa,Σb, δǫ, δe; (ii) we update bi and ai (i = 1, 2, · · · , n) using the Metroplis-Hastings
(M-H) algorithm. After collecting the final MCMC samples, we are able to draw statistical inference
for the unknown parameters. Specifically, we are interested in the posterior means and quantiles.
See the articles (Huang et al., 2006; Lunn et al., 2000) for detailed discussions of the Bayesian
modeling approach and the implementation of the MCMC procedures, including the choice of the
hyper-parameters, the iterative MCMC algorithm, the choice of proposal density related to M-H
sampling, sensitivity analysis and convergence diagnostics. When the MCMC implementation is
applied to the actual clinical data, convergence of the generated samples is assessed using standard
tools within WinBUGS software (such as trace plots). After convergence was achieved, one long
chain was run which may be more efficient. We propose that, after an initial number of 50,000 burn-
in iterations, every 40th MCMC sample is retained from the next 400,000. Thus we obtain 10,000
samples of targeted posterior distributions of the unknown parameters for statistical inference.
We will investigate the following two scenarios. Firstly, As shown in Figure 3.1, the histograms
of viral load and CD4 cell count clearly indicate their asymmetric nature and it seems adequate
fitting an SN model to the data set. Since a normal distribution is a special case of an SN distri-
bution when skewness parameter is zero, we will investigate how an SN distribution for random
error contributes to modeling results and parameter estimation in comparison with a normal dis-
tribution for random error. Secondly, we also estimate the model parameters by using the ‘naive’
method, which does not separate the measurement errors from the true CD4 values (i.e., completely
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ignores measurement errors in CD4 values in the modeling). That is, the ‘naive’ method only uses
the observed CD4 values zij rather than true (unobservable) CD4 values z∗ij in the response Models
I–II in which case the joint models revert to regular models without covariate models involved for
inference. We use the ‘naive’ method as a comparison to the joint modeling method proposed in
Section 3.2. This comparison attempts to investigate how the measurement errors in CD4 contribute
to parameter estimation.
3.3.2.1. Comparison of results between models with normal and SN distributions
As discussed previously, the fundamental assumption of distributions for (within-subject) random
error in Models I–III is SN which is different from that of normal distribution in most statistical
models in publications (Liu and Wu, 2007; Perelson et al., 1997; Wu et al., 1998; Wu and Ding,
1999; Wu and Zhang, 2002). In this section, we investigate how an SN distribution contributes to
modeling results in comparison with a normal distribution for random error.
The population posterior mean (PM), the corresponding standard deviation (SD) and 95% cred-
ible interval (CI) for fixed-effect parameters based on the models with an SN or normal random
errors are presented in Table 3.1. The following findings are observed based on the estimated re-
sults. (i) Firstly, in the response models for the most interested parameters (β2, β4, β5), β2 based
on the three models with a normal random error are larger than the corresponding that based on the
three models with an SN random error; all the estimates are statistically significant since the 95%
CIs do not contain zero. Secondly, for (β4, β5), it can be seen that the estimates based on the SN-
BNLME and SN-BSNLME models are substantially different from those based on the N-BNLME
and N-BSNLME models. Thirdly, for the variance parameter σ2, its estimated values (0.04, 0.08,
0.09) based on the three models with a SN random error are much smaller than those (0.96, 0.54,
1.31) based on the three models with a normal random error. Finally, for the skewness parameter
δe, we found that δe associated with the three models with an SN random error is estimated to be
significantly positive; this confirms the positive skewness of the viral load data in ln scale as shown
in Figure 3.1, and the estimates of the skewness parameter δe based on SN-BLME model (1.57),
SN-BNLME model (1.15) and SN-BSNLME model (2.03) are fairly high. (ii) For estimated pa-
rameters in the CD4 covariate models, the estimates of intercept α1 based on the N-BNLME and
N-BSNLME models are larger than those based on SN-BNLME and SN-BSNLME models, how-
ever the estimates of coefficients α2 and α3 are very similar between SN and normal models. For the
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variance parameter τ2, the estimated values (0.10, 0.13) based on the N-BNLME and N-BSNLME
models are larger than those (0.01, 0.08) based on SN-BNLME and SN-BSNLME models. The
estimates of the skewness parameter δǫ based on SN-BNLME and SN-BSNLME models are signif-
icantly positive which is consistent with positive skewness of the CD4 cell count data as shown in
Figure 3.1.
Table 3.1: A summary of the estimated posterior mean (PM) of interested population (fixed-effects)
and precision parameters
Model α1 α2 α3 β1 β2 β3 β4 β5 τ 2 σ2 δǫ δe
N-BLME PM – – – 8.01 3.70 – – – – 0.96 – –
LCI – – – 7.52 3.16 – – – – 0.74 – –
UCI – – – 8.51 4.22 – – – – 1.25 – –
SD – – – 0.25 0.27 – – – – 0.13 – –
SN-BLME PM – – – 5.42 3.43 – – – – 0.04 – 1.57
LCI – – – 4.80 2.85 – – – – 0.01 – 1.34
UCI – – – 6.03 4.04 – – – – 0.18 – 1.83
SD – – – 0.31 0.30 – – – – 0.05 – 0.13
N-BNLME PM -0.20 0.68 -0.42 8.52 21.0 5.59 1.26 0.04 0.10 0.54 – –
LCI -0.47 0.15 -0.98 7.96 16.6 5.01 0.60 0.01 0.08 0.40 – –
UCI 0.07 1.19 0.14 9.09 26.3 6.15 1.91 0.33 0.13 0.73 – –
SD 0.14 0.26 0.28 0.28 2.44 0.29 0.33 0.19 0.13 0.08 – –
SN-BNLME PM -1.01 0.70 -0.50 6.70 20.9 3.82 1.35 0.02 0.01 0.08 0.53 1.15
LCI -1.30 0.24 -0.99 5.97 16.6 3.03 0.64 0.01 0.01 0.01 0.38 0.79
UCI -0.70 1.16 0.04 7.50 26.0 4.60 1.97 0.22 0.05 0.33 0.65 1.42
SD 0.16 0.24 0.27 0.39 2.39 0.39 0.34 0.15 0.01 0.09 0.07 0.16
N-BSNLME PM -0.22 0.66 -0.28 8.29 26.6 3.66 -2.56 0.88 0.13 1.31 – –
LCI -0.48 0.13 -0.85 7.75 17.5 1.12 -10.6 0.31 0.10 1.06 – –
UCI 0.03 1.20 0.29 8.83 36.2 5.27 2.90 1.77 0.15 1.62 – –
SD 0.13 0.27 0.29 0.28 4.77 1.02 3.33 0.45 0.01 0.14 – –
SN-BSNLME PM -0.62 0.65 -0.27 4.60 17.1 -0.09 -4.44 0.15 0.08 0.09 0.25 2.03
LCI -1.13 0.10 -0.85 3.76 9.97 -2.76 -10.9 0.06 0.04 0.01 0.16 1.64
UCI 0.37 1.19 0.31 5.63 23.0 1.50 -0.60 0.94 0.13 0.38 0.52 2.34
SD 0.41 0.27 0.29 0.47 3.41 1.14 2.83 0.39 0.03 0.10 0.25 0.17
SN-BSNLME PM – – – 5.34 28.1 1.57 0.39 0.78 – 0.12 – 1.84
(NV) LCI – – – 4.55 20.7 0.22 -3.98 0.17 – 0.01 – 1.45
UCI – – – 6.18 36.7 2.73 3.57 1.37 – 0.43 – 2.18
SD – – – 0.41 3.99 0.64 1.92 0.32 – 0.12 – 0.18
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Figure 3.4: The individual estimates of viral load trajectories for three randomly selected patients
based on the BLME (left), BNLME (center) and BSNLME (right) models with a normal (dotted
line) or SN (solid line) random errors. The respective vertical dotted line (normal) ended with ‘◦’
and solid line (SN) ended with ‘•’ on each fitted value are the 95% credible interval (CI) associated
with the fitted value. The observed values are indicated by sign crosses (×).
Figure 3.5 displays the three randomly selected individual estimates of viral load trajectories
along with the associated 95% CIs on each fitted value obtained based on the BLME (left), BNLME
(center) and BSNLME (right) models with a Normal (dotted line) or SN (solid line) random error,
respectively. The following findings are observed from joint modeling results. (i) The estimated
individual trajectories for the models where the random error is assumed to be SN fit the originally
observed values much closer than those for the corresponding models where the random error is
assumed to be normal. (ii) Overall, the 95% CI associated with each of fitted values from the
normal models is wider than that from the corresponding SN models. (iii) All the 95% CIs from
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three SN models cover the true (observed) viralr load values, while some of 95% CIs from three
normal models do not. For example, for patient 39 whose observed value at day 115 is 10.57,
the 95% CI from the SN-BSNLME model is (9.90,11.02) with the fitted value 10.51, while the
corresponding 95% CI from the N-BSNLME model is (7.19, 9.53) with the fitted value 8.33 which
does not cover the observed value 10.57.
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Figure 3.5: The observed values versus fitted values of ln(RNA) based on the BLME (left), BNLME
(center) and BSNLME (right) models with a normal or SN random error.
We also investigate the model fitting results for each of the three mixed-effects models with
normal and SN random errors, respectively. We have seen that, in general, all the models provided
a reasonably good fit to the observed data for most patients in our study, although the fitting for a
few patients was not completely satisfactory due to unusual viral load fluctuation patterns for these
patients. To assess the goodness-of-fit of each of the three mixed-effects models with normal and
SN random errors, the diagnostic plots of the observed values versus the fitted values are presented
in Figure 3.5. It was seen from Figure 3.5 that the models where the random error is assumed to
be SN provided better fit to observed data, compared with the models where the random error is
assumed to be normal. This finding is further confirmed by their residual sum of squares (RSS).
That is, for the BLME model the RSSs are 3.62 (SN random error) and 117.37 (normal random
error); for the BNLME model the RSSs are 6.64 (SN random error) and 63.78 (normal random
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error); for the BSNLME model the RSSs are 7.49 (SN random error) and 312.58 (normal random
error).
For selecting the best model that fits the data adequately, a Bayesian selection criterion is used.
This criterion, known as deviance information criterion (DIC), was first suggested in a recent pub-
lication by Spiegelhalter et al.(2002). As with other model selection criteria, we caution that DIC
is not intended for identification of the ‘correct’ model, but rather merely as a method of compar-
ing a collection of alternative formulations. In each of the three models with the specification of
different distributions for the random error, DIC can be used to find out how assumption of an SN
distribution contributes to virologic responses and parameter estimation in comparison with that
of a normal distribution. We found that the DIC values, 335.14 (SN-BLME), 607.24 (SN-NLME)
and 1051.21 (SN-SNLME) for the three models with an SN random error are smaller than the cor-
responding ones, 524.54 (normal-BLME), 701.17 (normal-NLME) and 1355.45 (normal-SNLME)
for the three models with a normal random error, respectively.
As mentioned before, it is hard to tell which model is ‘correct’ but which one fits data better.
Therefore, based on the DIC criterion, the results indicate that each of the three models with an SN
random error fits the data better, supporting the contention of a departure from normality. These
results are consistent with those from diagnosis of the goodness-of-fit displayed in Figure 3.5. In
summary, our results may suggest that it is very important to assume an SN distribution for the
response models in order to achieve reliable results, in particular if data exhibit skewness. Along
with these observations, we further report our results in details only for the three models with an SN
random error.
3.3.2.2. Results of analysis based on the SN models
The population (average) estimates of the viral dynamic parameters presented in Table 4 based on
the three (SN-BLME, SN-BNLME, SN-BSNLME) models indicate that the estimates of β1 from
the different models agree fairly well. However, the estimates (20.9 and 17.1) of the first decay
rate β2 by SN-BNLME and SN-BSNLME modeling methods are significantly different from that
(3.43) obtained by SN-BLME modeling method. Although the estimates of β2 by SN-BNLME and
SN-BSNLME modeling methods are comparable, one problem is that we considered only 84-day
data for SN-BNLME model fit. This means that only 68% of the data from the 168-day period
were included due to arbitrary truncation of data. Therefore, the SN-BNLME modeling may not
63
be efficient. In this case, we prefer to use the SN-BSNLME model in which a smooth function of
treatment time is incorporated into the second-phase decay rate to better catch rebound viral load
data and all data measured during the treatment period can be used.
In the SN-BLME and SN-BNLME model fittings, individual curves (solid lines in Figure 3.5)
for each subject follow a similar trend; that is, the trajectories of viral load decay in all 3 subjects
decrease rapidly in the first-phase, then flatten in general. When the entire treatment period is con-
sidered, the viral loads of subject 39 rebound after the second-phase, whereas the viral loads of
subjects 23 and 32 remain low until the end of the treatment period. Obviously, the SN-BLME
and SN-BNLME model fittings are reasonable for data cutting at days 35 and 84, but they do not
represent data measured over the whole treatment period.
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(a) Modle I: r= 0.874 ,  p<0.0001
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(b) Modle II: r= −0.952 ,  p<0.0001
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(c) Modle III: r= 0.727 ,  p<0.0001
Figure 3.6: Correlations between baseline ln(RNA) levels and the subject-specific first phase viral
decay rates, βi1 estimated by using each of the three different methods. The solid lines are robust
(MM-estimator) linear regression fit. The correlation coefficients (r) and p-values were obtained
from Spearman rank correlation test.
It is also worth noting the differences among the estimated values of the first-phase decay rate
(β2) for each subject based on the three models. We can see from Figure 3.6 (top panel) that the
individual estimated values of β2 obtained by the SN-BNLME model fitting are consistently much
greater than those obtained by the SN-BLME model fitting, but are slightly different from those
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obtained by the SN-BSNLME model fitting. Although for each model the individual estimates of
ln(RNA) levels approximately follow the observed values, the differences in β2 values obtained
with each model may suggest a completely different relation between β2 and baseline viral loads.
When we investigate the relation between the estimated individual first-phase decay rates β2 and
baseline ln(RNA) levels, the results are incongruous. The correlations between the subject-specific
viral decay rates β2 estimated by each method and baseline ln(RNA) levels are shown in Figure 3.6
(bottom panel). The subject-specific estimates of β2 obtained from the SN-BSNLME and SN-
BLME modeling methods show significantly positive correlations (rI = 0.727 and rIII = 0.874
with p-value p < 0.0001) with baseline ln(RNA) levels. However, the estimates of β2 obtained
by using the SN-BNLME modeling method are negatively correlated with baseline ln(RNA) levels
(rII = −0.952 with p-value p < 0.0001).
The incongruity in the individual estimates of the first-phase viral decay rates and their cor-
relations with baseline ln(RNA) levels, as determined by the SN-BLME, SN-BNLME and SN-
BSNLME modeling methods, is significantly different with the following two observed scenarios:
(i) Although the individual estimates of β2 obtained by the both SN-BLME and SN-BSNLME mod-
eling methods are positively correlated with baseline ln(RNA) levels, the the individual estimates of
β2 from the SN-BSNLME method are, in general, five times larger than those from the SN-BLME
method. (ii) The individual estimates of β2 by SN-BNLME and SN-BSNLME modeling methods
are fairly comparable, but the correlations between baseline ln(RNA) levels and the subject-specific
viral decay rates β2 estimated by these two methods are completely opposite. These inconsistences
are presumably caused by data truncation. From the above results, it may suggest that the estimates
obtained from the both SN-BLME and SN-BNLME models might be not reliable and the estimates
based on the SN-BSNLME model may be favorable.
To fit the SN-BLME model, we truncated the data at day 35 in this study. However, it is not
clear where one should cut the data between the first- and second-phases of decay. Also, different
subjects may have different change points between the two phases. For example, truncation at day
35 may cause data from the second-phase to be included with first-phase data. It is for this reason
that SN-BLME models underestimate the first-phase decay rates (β2). The SN-BSNLME modeling
method is preferable to the SN-BLME and SN-BNLME modeling methods, especially for sparse
individual data. We believe that estimates obtained from the SN-BSNLME modeling method and
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their correlations with baseline ln(RNA) levels are reliable since the complete data are used. Con-
versely, the both SN-BLME and SN-BNLME model fittings may result in misleading conclusions,
as shown above, perhaps because it is impossible to find a truncation point to data for these two
model fittings that would be suitable for all patients. The estimated values of β2 would be affected
by the inclusion of second-phase data if truncation occurred too late, and by the loss of data if trun-
cation was too early.
For comparison, as an example, we also employed the ‘naive’ method-based the SN-BSNLME
model to estimate the model parameters presented in Table 3.1 using the observed CD4 values and
ignoring the CD4 measurement errors. It can be seen from the estimated results that the estimates
of the parameters from the naive method are significantly larger than those from the joint modeling
method. It indicates that the naive method may produce overestimated results with substantial bi-
ases; in particular, the estimated covariate CD4 effect (β5) from the naive method is 5 times greater
than that from the joint modeling method. The joint modeling method appears to give larger SDs
in most cases, probably because it incorporates the variation from fitting the CD4 covariate pro-
cess. Further, the estimate of the model skewness parameter δe for the naive method is slightly
smaller than that for the joint modeling method; this result suggests that the naive method may un-
derestimate the skewness parameter due to ignoring measurement errors in CD4 values. Thus the
difference of the naive estimates and the joint modeling estimates, due to whether or not ignoring
potential CD4 measurement errors in conjunction with the SN-BSNLME model, indicates that it is
important to take the measurement errors into account in the analysis when covariates are measured
with errors.
3.4. Discussion
For viral dynamic models with skewness characteristics of viral load responses and CD4 measure-
ment errors in covariate, we have investigated and compared the three Bayesian mixed-effects mod-
els with an SN distribution that may be preferred over those with a normal distribution in the sense
that it produces less biased parameter estimates and provides better fit to observed data. The pro-
posed method may have a significant impact on AIDS research because, in the presence of skewness
in the data, appropriate statistical inference for HIV dynamics is important for making robust con-
clusions and reliable clinical decisions. Our proposed method is quite general and so can be used
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to other applications. This kind of SN modeling approach is important in many biostatistical appli-
cation areas, allowing accurate inference of parameters while adjusting for the data with skewness.
The SN distribution is shown to provide an alternative to normal (symmetric) distribution that is
often assumed in statistical models. The results indicate that with SN distribution assumption, there
is potential to gain efficiency and accuracy in estimating certain parameters when the normality as-
sumption does not hold in the data. The models considered in this paper can be easily fitted using
MCMC procedure. Moreover, the proposed modeling approach is fitted using the WinBUGS pack-
age that is available publicly. This makes our approach quite powerful and accessible to practicing
statisticians in the fields.
To estimate the viral dynamic parameters and study the relation of the baseline level of HIV-1
RNA in plasma with the decay rate of the first-phase of response to treatment, we compared the
results of SN-BLME, SN-BNLME and SN-BSNLME model fittings, and found that the both SN-
BLME and SN-BNLME model fittings in short-term dynamics may result in misleading conclusions
due to data truncation. Of particular interest is that when long-term dynamics are considered, SN-
BNLME may also become unreliable because of the complexity of the second-phase of decay. The
foregoing results indicate that in a two-phase HIV dynamic model, the first decay rate may remain
constant, while the second decay rate may change which depends on time-varying CD4 covariate
during the period of study. The analysis results suggest that there may be a significantly posi-
tive correlation between the first-phase viral decay and the baseline HIV-1 RNA levels based on
the SN-BSNLME modeling method. This finding is consistent with those reported in publications
(Notermans et al.,1998; Wu et al., 2004). This positive correlation may be partially explained by the
fact that the higher baseline viral load value, which is equivalent to the lower baseline CD4 value
due to a negative relation between these two baseline factors, suggests a lower turnover rate of hym-
phocyte cells, which may lead to a positive correlation between the first-phase viral decay rate (β2)
and the baseline HIV-1 RNA levels. Higher baseline HIV-1 RNA levels reflect more productively
infected cells distributed at different sites; thus, greater drug potency or exposure may be required
to achieve a similar decay rate to that seen in patients with lower levels of viral replication. This
finding is very interesting and clinically important. Since the viral decay rates may reflect the effi-
cacy of ARV treatment, the lower baseline HIV-1 RNA levels may need less potent drug efficacy to
suppress virus replication so that a strong treatment strategy is not necessary to avoid side-effect of
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drug use. This may help improve understanding of the pathogenesis of HIV infection and evaluation
of ARV treatments.
We would point out that the problems we have addressed in this paper cannot be resolved by
the standard goodness-of-fit or model selection methods, which are usually used when applying
different models to the same data set. From Figure 3.5, we can see that all three models (BLME,
BNLME and BSNLME) fitted the corresponding data very well. Goodness-of-fit or model selection
methods are unable to identify the right model. We have found that the different models should not
be applied to the same, entire data set, but applied simultaneously to appropriate segments of the
data set such that the results will be biologically meaningful.
In conclusion, BLME fitting may be misleading and its use should be avoided; BNLME fit-
ting may work well but is subject to data truncation; BSNLME fitting works in a similar way to
BNLME fitting but has no data-screening problems associated with its use. Care is necessary in the
implementation of BNLME and BSNLME fittings. With the introduction of SN distribution in the
models, the estimated results suggest that the skewness parameters in viral load and CD4 cell count
are estimated to be significantly positive for each of the three models. This confirms the positive
skewness of the viral load and CD4 data presented in Figure 3.1. Thus, we may conclude that ac-
counting for significant skewness is required when one models a data which exhibits skewness.
This paper combines new technologies in mathematical modeling and statistical inference with
advances in viral dynamics and ARV treatment to quantify complex HIV disease mechanisms. The
complex nature of HIV/AIDS will naturally pose some challenges such as nonignorable missing
data and data with detection limit problems. These complicated problems are beyond the purpose
of this article, but a further study may be warranted. We are actively investigating these problems
now. We hope that we could report these interesting results in the near future.
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4 Bivariate linear mixed-effects models with an application to AIDS
study using skew-elliptical distributions
4.1. Introduction
Multivariate or bivariate outcomes are used as primary endpoints in many longitudinal studies. For
example in AIDS studies, not only the RNA viral load, but also the CD4 and CD8 cell count are
measured (Acosta et al., 2004). HIV-1 infection results in a progressive destruction of immune func-
tion, which may be indicated by a decrease of CD4 cell count and an increase of CD8 cell count.
Studies of changing immunologic CD4 and CD8 responses may be important to identifying indica-
tors for quantifying treatment effect and to improving management of patient care. With this type of
multiple outcomes (CD4 and CD8 cell count), the underlying statistical question is to estimate the
functions that model their dependence on co-variates and to investigate the relationships between
these functions. Similar clinical and epidemiological studies often generate clustered as well as
longitudinal follow-up data with bivariate or multivariate outcomes as primary endpoints, which are
routinely analyzed using multivariate linear mixed-effects models (Matsuyama and Ohashi, 1997).
In this chapter, we focus on a bivariate LME (BLME) model on the situation where two response
variables (CD4 and CD8 cell count) are observed simultaneously for each subject to accommodate
individual clustering within subjects as well as the correlation between bivariate measures. BLME
can facilitate borrowing of strength across all subjects when assessing the effects of co-variates
through treatment time, baseline age, treatment group, viral load at baseline and time-varying treat-
ment efficacy, etc. on AIDS progression. Thus, in particular, a BLME model is used to estimate
various parameters including the correlation coefficients between CD4 and CD8 cell count. CD4 cell
count is an important indicator of the strength of the immune system. CD4 cells are ‘helper’ cells
that lead the attack against infections and are considered as the HIV main target cells. CD8 cells are
‘cytotoxic’ cells and are inappropriately “on” or active in terms of the immune hormones secreted
during HIV infection. The hyperdynamic or over-stimulated CD8 immune response, reflected by
activation of CD8 subsets as well as elevated total CD8 cell count, may accelerate immune dysfunc-
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tion and certain disease processes. The ratio of CD4 and CD8 cell count is important in monitoring
the function of the immune system in patients who have viral infections or who have undergone
tissue transplantation.
In traditional LME model analysis (Laird and Ware, 1982), the correlation due to clus-
tered/repeated measures on a subject is usually accounted for through the inclusion of random-
effects and within-subject measurement errors, which are often assumed to be normally distributed
due to the mathematical tractability and computational convenience. While such an assumption
makes data analysis amenable to popular software such as SAS and R/Splus, the usual fidelity to
normality assumptions has been questionable (Ghidey et al., 2004; Verbeke and Lesaffre, 1996)
when data exhibit non-normal behavior. A violation of the assumption could lead to misleading
inferences. In fact, observed data in AIDS studies are often far from being “symmetric” and asym-
metric patterns of observations usually occur. A common approach adopted for data analysis in
these situations is reverting back to usual multivariate normality assumptions after suitable trans-
formation of the response on a continuous scale (e.g. square-root transformation of CD4 and CD8
cell count). Although they may lead to reasonable empirical results, they may be avoided when
a suitable alternative theoretical model is available because data transformation hinds underlying
data generation mechanisms due to reduced information and often component-wise transformation
does not lead to joint normality (Jara et al., 2008). Besides, the transformations are not universal,
i.e. transforms used for one particular data may not be adapted for a different data. Moreover, the
results may be difficult to interpret based on transformed data. This motivates researchers to con-
sider exploration of a more general mixed effects framework that takes into account the flexibility
in distributional assumptions of random-effects and measurement errors to produce robust parame-
ter estimates. The term ‘robustness’ is quite extensive; here robustness is achieved with respect to
parameter estimation.
Considerable research has been done by introducing more flexible parametric families that can
accommodate normality departures (skewness and heavy tails) and hence eliminate the need of
ad hoc data transformations (Azzalini and Capitanio, 1999). In the context of LME models, the
random-effects distribution was relaxed using finite normal mixtures (Verbeke and Lesaffre, 1996),
smoothing (Ghidey et al., 2004), a semi-nonparametric density (Zhang and Davidian, 2001) or a
thick-tailed normal/independent (NI) densities (Rosa et al., 2003). Much of recent frequentist and
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Bayesian advances in regression problems revolve around the attractive and popular skew-elliptical
distributions (Azzalini and Capitanio, 1999, 2003; Azzalini and Dalla-Valle, 1996; Sahu et al.,
2003). The related literature in this context is very rich (Arellano-Valle et al., 2006; Azzalini, 2005;
De la Cruz, 2008; Lin, 2009) and the curious reader might choose to venture an entire monograph
(Genton, 2004) dedicated to discuss recent developments. A common feature of these classes of
models is that the normal linear mixed model is a special member in each class. In this chapter, we
propose a parametric modeling of LME model for robust estimation using SE distributions under a
Bayesian paradigm. The multivariate SE distributions used in this chapter are developed primarily
from the multivariate SE density proposed by Sahu et al.(2003) for Bayesian regression problems
and is different from the SE version proposed by Azzalini and Dalla-Valle (1996). However, the
differences are only due to the various parameterizations (Arellano-Valle and Azzalini, 2006) used
and an unification of all SE variants is presented by Arellano-Valle and Genton (2005). Recent
Bayesian implementation of multivariate SE distributions (Jara et al., 2008) involves SN and ST
densities using a conditional stochastic representation. Three distributions, N, SN and ST will be
considered in this chapter.
The rest of the chapter proceeds as follows. In Section 4.2, we describe the data set that mo-
tivated this research and introduce BLME models. Section 4.3 presents the associated Bayesian
inference method and related model comparison techniques. In Section 4.4, we apply the proposed
method to the real data set described in Section 4.2 and report the analysis results. We conclude the
chapter with discussion in Section 4.5.
4.2. Data and models with the skew-elliptical distributions
4.2.1. Motivating data set
The data set that motivated this research is from A5055 and some detail information about this data
set can be found in Section 2.4.1. and 3.3.1. Besides the HIV-1 viral load in plasma, CD4 and CD8
cell count in peripheral blood were designed to be measured in cells/mL at the same schedule as
HIV, which was days 0, 7, 14, 28, 56, 84, 112, 140 and 168 of follow-up.
CD4 and CD8 cell count: CD4 and CD8 cell count were measured in cells/mL at designed
study days. The median value at the baseline (t = 0) is 262/mL for CD4 and 880/mL for CD8
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cell. The exact day of CD4 and CD8 cell count measurements (not predefined study day) was used
to compute study day in our analysis. It is noted that observed data in the AIDS studies are often
far from being “symmetric” and skewed heavy tailed patterns in CD4 and CD8 cell count usually
occur (Figure 4.1). Thus, an asymmetric distribution (such as SE) should be more appropriate than
a symmetric distribution, and statistical analysis must take these features of the data into account.
Figure 4.2 shows the trajectories of observed CD4 and CD8 cell count (in standardized scale) after
the initiation of an ARV treatment for 44 patients.
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Figure 4.1: The histogram of CD4 and CD8 cell count (standardized scale) measured in peripheral
blood for 44 patients.
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Figure 4.2: The trajectory profiles of CD4 and CD8 cell count (standardized scale) measured in
peripheral blood for 44 patients.
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Figure 4.3: The baseline (◦) and failure time(×) IC50 for IDV/RTV drugs (top panel), the minimum
drug concentration (Cmin) for two drugs (middle panel) for the 44 individual patients and adherence
rates of IDV/RTV drugs (bottom panel) over time for the two representative patients. SD and CV
denote the standard deviation and coefficient of variation, respectively.
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Phenotypic drug susceptibility: Phenotypic drug susceptibilities were retrospectively deter-
mined from baseline samples. Phenotypic determination of ARV drug resistance was performed at
baseline and/or at the time of virological failure (viral load rebounds). Some patients had virologic
failure and phenotypic susceptibility testing done on samples at the time of failure. For analysis,
we used the phenotype marker, the median inhibitory concentration (IC50) (Molla et al., 1996) to
quantify agent-specific drug susceptibility. We refer to this marker as the median inhibitory con-
centration. The baseline (◦) and failure time(×) IC50 from 44 individuals for the two agents used
in the A5055 trial, ritonavir (RTV) and indinavir (IDV), are displayed in Figure 4.3 (upper panel)
which were used to construct IC50(t). Note that for patients without virological failure, IC50(t)
was held by a constant with the baseline IC50 over time.
Pharmacokinetics variation: Plasma for intensive Pharmacokinetics (PK) analysis was ob-
tained at pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours following an observed IDV/RTV
dose. PK parameters of IDV and RTV were determined using non-compartmental methods. Cal-
culated PK parameters included maximum (Cmax), minimum (Cmin) drug concentration, and area
under the curve (AUC). Wu et al.(2006) compared these PK parameters as predictors of virological
responses and no significant differences were found. Thus, Cmin displayed in Figure 4.3 (middle
panel) was used in our analysis because it is easily obtained in clinical studies.
Medication adherence: Medication adherence was measured by the use of questionnaires. It
was completed by the study participant and/or by a face-to-face interview with study personnel. As
an example, the adherence rates over time based on questionnaire data for IDV (dotted stair-step
line) and RTV (dashed stair-step line) drugs from the two representative patients are presented in
Figure 4.3 (bottom panel).
Time-varying drug efficacy: We briefly discuss the drug efficacy function with two or more
agents. In clinical practice, genotypic or phenotypic tests can be performed to determine the sensi-
tivity of HIV-1 to ARV agents before a treatment regimen is selected. Here we use the phenotypic
marker, IC50, half maximal inhibitory concentration, to quantify agent-specific drug susceptibility.
Because experimental data tracking development of resistance suggest that the resistant fraction of
the viral population that grows exponentially, we propose a ln-linear function to model the within-
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host changes over time based on available IC50 observations as follows.
IC50(t) =


ln(S0 +
Sr−S0
tr
t) for 0 < t < tr
ln(Sr) for t ≥ tr
(4.1)
where S0 and Sr are respective exponential values of IC50 at baseline and time point tr at which the
resistant mutations dominate. In our study, tr is the observed time of virologic failure from clinical
studies. Given that IC50 is measured only at baseline and at the time of treatment failure (Molla et
al., 1996), IC50(t) remains practical although more complex models for IC50(t) can be considered.
For patients without a failure time IC50, baseline IC50 was held constant over time. In other words,
if Sr = S0, no new drug resistant mutation is developed during treatment.
Poor adherence to a treatment regimen is one of the major causes of treatment failure (Ickovics
and Melisler, 1997). Patients may occasionally miss doses, misunderstand prescription instructions
or miss multiple consecutive doses for various reasons. These deviations from prescribed dosing
affect drug exposure in predictable ways. We use the following model to represent medication
adherence,
A(t) =


1 for Tk < t ≤ Tk+1, if all doses are taken in [Tk,Tk+1]
R for Tk < t ≤ Tk+1, if 100R% doses are taken in [Tk,Tk+1]
(4.2)
where 0 ≤ R < 1, with R indicating the adherence rate for a drug (in our study, we focus on
the two PI drugs discussed previously). Tk denotes the adherence evaluation time at the kth clin-
ical visit. HAART contains two or more reverse transcriptase inhibitors (RTIs) and protease in-
hibitors (PIs) has proven to be effective at reducing the amount of virus in the blood and tissues
of HIV-infected patients. In most viral dynamic studies (Ding and Wu, 2000; Perelson et al.,
1996), investigators assumed that the drug efficacy was constant over treatment time. Drug effi-
cacy may actually vary, however, because the concentrations of ARV drugs and other factors (i.e.,
emergence of drug-resistant mutations) vary during treatment. Also, patients’ viral load may re-
bound because of drug resistance, non-adherence, and other factors. A simple pharmacodynamic
(PD) sigmoidal Emax model for the dose effect relation follows (Gabrielsson and Weiner, 2000):
E = EmaxC/(EC50 + C), where Emax is the maximal effect that can be achieved, C is the drug
concentration, and EC50 is the drug concentration that induced an effect equivalent to 50% of the
maximal effect. Many different variations of the Emax model have been developed by pharmacol-
ogists to model PD effects. More detailed discussions on Emax models can be found in the book
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by Gabrielsson and Weiner (2000) and in the article by Huang et al.(2003). To model the relation-
ship of multiple treatment factors with ARV drug efficacy, we employ the following modified Emax
equation to represent the time-varying drug efficacy for two ARV agents within a class,
γ(t) =
1
2
{
C1minA1(t)
IC150(t) + C
1
minA1(t)
+
C2minA2(t)
IC250(t) + C
2
minA2(t)
}
(4.3)
where γ(t) ranges from 0 to 1; Ad(t), Cdmin and ICd50(t) (d = 1, 2) are the adherence profile, the
minimum drug concentration in plasma and the time-course of median inhibitory concentrations for
the two agents, respectively. Note that Cmin could be replaced by other PK parameters such as
AUC and Cmax.
4.2.2. Bivariate linear mixed-effects models with ST distribution
Now we summarize the LME model for the AIDS data with bivariate correlated responses (CD4
and CD8 cell count). Let y(c)i = (y(c)i1 , y(c)i2 , . . . , y(c)ini)T , (c = 4, 8) be the repeated measure-
ments (in cells/mm3) of the CD4 and CD8 cell count, respectively, for the ith subject at time
tij (i = 1, 2, ..., n, j = 1, 2, ..., ni). Associated with each vector of measurements is a vector of
times ti = (ti1, . . . , tini)T at which subject’s measurements were taken. Let x(4)i and x(8)i be the
ni × p design matrices associated with the fixed-effects β(4) and β(8) of the two markers, respec-
tively, and z(4)i and z
(8)
i be the corresponding ni × q design matrices associated with the random-
effects b(4)i and b
(8)
i , respectively. To make notation more compact, let Y i =
(
y
(4)T
i ,y
(8)T
i
)T
,
Xi =Diag
(
x
(4)
i ,x
(8)
i
)
, Zi =Diag
(
z
(4)
i ,z
(8)
i
)
, β =
(
β(4)T ,β(8)T
)T
, bi =
(
b
(4)T
i , b
(8)T
i
)T
,
ei =
(
e
(4)T
i ,e
(8)T
i
)T
, where e(4)i and e
(8)
i are the within-subject residuals for CD4 and CD8 cell
count, respectively. As suggested by Lachos et al. (2009, 2010), we consider a skew-t bivariate LME
(ST-BLME) model in which the within-subject errors are assumed to follow a normal distribution
and the random-effects (latent random variables) are assumed to have an ST distribution which may
be more reasonable. Thus, we have a skew-t bivariate LME (ST-BLME) model as follows,
Y i = X iβ +Zibi + ei
bi ∼ ST2q,ν(−J(ν)δ,Σb,∆)
ei ∼ N2ni(02ni ,Σ)
(4.4)
where Σb = (λkl)4×4 is the dispersion matrix corresponding to between-subject variability for
random-effects, Σ = (σ2kl)2×2 is variance-covariance matrix for model errors, ∆ = Diag(δ) and
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δ = (δ1, . . . , δ2q)
T
, and J(ν) = (ν/π)1/2[Γ((ν − 1)/2)/Γ(ν/2)]. Note that, in the model (4.4),
the correlation between the bivariate responses is accommodated and incorporated by both random-
effects bi and model errors ei.
4.3. Bayesian Inference
In this section, we implement the Bayesian methodology using MCMC techniques for the ST-BLME
model. A key feature of this model, which allows writing easily WinBUGS codes, is that the model
can be formulated in a flexible hierarchical representation. By introducing one random variable
vector, wi = (wi1, ..., wi2q)T and one random variable, ξi, (i = 1, ..., n), based on the stochastic
representation for the ST distribution (see Section 1.4 in detail), Y i in the ST-BLME model (4.4)
can be written hierarchically as
Y i|wi, ξi ∼ N2ni(X iβ +Zibi, ξ−1i Σ)
bi ∼ N2q(∆wi − J(ν)δ, ξ−1i Σb)
wi ∼ N2q(0, I2q)I(wi > 0)
ξi ∼ Γ(ν/2, ν/2)
(4.5)
where (i = 1, . . . , n). An important advantage of the above representations based on the hierar-
chical model is that they allow us to easily implement the ST-BLME model via the freely available
WinBUGS software (Lunn et al., 2000), and the computational effort is similar to the one necessary
to fit the models with the standard normal distribution. Our methodology can be widely applied
to real problems for longitudinal studies as long as they meet the specifications proposed in this
chapter.
Let θ = {β(4),β(8),Σ, δ,Σb, ν} be the collection of unknown parameters in model (4.4),
y = (yT1 , ...,y
T
n )
T
, b = (bT1 , ..., b
T
n )
T
, w = (wT1 , ...,w
T
n )
T and ξ = (ξ1, ..., ξn)T , then the full
likelihood function is given by
L(θ|y, b,w, ξ) ∝ Πni=1{φ2ni(yi;X iβ +Zibi, ξ−1i Σ)φ2q(bi;∆wi − J(ν)δ, ξ−1i Σb)
φ2q(wi; 0, I2q)I(wi > 0)Γ(ν/2, ν/2)}
(4.6)
To complete the Bayesian formulation, we specified the values of the hyper-parameters in the
prior distributions and took weakly informative prior distribution for the parameters as follows
β ∼ N2p(β0,G1), Σb ∼ IW (G2, η1), Σ ∼ IW (G3, η2),
δ ∼ N2q(0,G4), ν ∼ Exp(τ)I(ν > 2)
(4.7)
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where the mutually independent Inverse Gamma (IG), Normal (N ), Exponential (Exp) and In-
verse Wishart (IW ) prior distributions are chosen to facilitate computations (Gelman et al., 2003).
The super-parameter matrices G1, G2, G3 and G4 can be assumed to be diagonal for convenient
implementation.
One usually assumes that elements of the parameter vector θ are independent of each other,
i.e., π(θ) = π(β)π(Σ)π(δ)π(Σb)π(ν). After we specify the models for the observed data and
the prior distributions for the unknown model parameters, we can make statistical inference for
the parameters based on their posterior distributions under a Bayesian framework. Combining the
likelihood function (4.6) and the prior distributions, the joint posterior density of θ based on the
observed data D can be given by
f(θ|D) ∝ L(θ|y, b,w, ξ)π(θ) (4.8)
Distribution (4.8) is analytically intractable, and it is prohibitive to directly calculate the posterior
distribution of θ based on the observed data. As an alternative, MCMC procedures can be used to
sample based on (4.8) using the Gibbs sampler, from which features of marginal posterior distribu-
tion of interest can be inferred.
4.4. Data analysis
4.4.1. Specific model and implementation
We illustrate our method by applying it to the AIDS clinical data described in Section 4.2.1. We
consider the following BLME model for CD4 and CD8 cell count.
y
(c)
ij = β
(c)
0i + β
(c)
1i tij + β
(c)
4 Agei + β
(c)
5 log10(RNA)i + β
(c)
6 γ(tij) + e
(c)
ij ,
β
(c)
0i = β
(c)
0 + β
(c)
1 gi + b
(c)
0i ,
β
(c)
1i = β
(c)
2 + β
(c)
3 gi + b
(c)
1i ,
(4.9)
The BLME hierarchal models (4.9) can be formulated as follows.
y
(c)
ij = β
(c)
0 + β
(c)
1 gi + β
(c)
2 tij + β
(c)
3 (gi × tij) + β(c)4 Agei
+β
(c)
5 log10(RNA)i + β
(c)
6 γ(tij) + b
(c)
0i + b
(c)
1i tij + e
(c)
ij ,
(4.10)
where c = 4 and 8 correspond to CD4 and CD8 cell count, respectively, y(4)ij and y
(8)
ij are the respec-
tive standardized CD4 and CD8 cell count for the ith subject at time tij , Agei and log10(RNA)i are
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age and viral load (in log10 scale) covariates for the ith subject at baseline, γ(tij) is drug efficacy for
the ith subject at time tij , gi = 1 if the ith subject was treated in group one and 0 in group two. The
corresponding regression coefficient β(c)3 can be interpreted as the treatment effect between groups
one and two. b(c)0i and b
(c)
1i are random-effects representing a random intercept and a random slope,
respectively. This model assumes that the mean baseline measurement (intercept) and mean rate of
change (slope) are different between two treatment groups.
Several statistical models with different distribution from the SE class for the latent random-
effects and random errors are compared. These models are as follows.
• N Model: Normal distribution for the random-effects and random errors.
• SN Model: Skew-normal distribution for the random-effects and normal distribution for the
random errors.
• ST Model: Skew-t distribution for the random-effects and normal distribution for the random
errors.
Note that random-errors can also be assumed to follow skew-normal or skew-t distribution,
however, once the random-effects are assumed to be SN or ST distribution, the results are simi-
lar between normal and skewed distribution for random errors assumption. In order to make the
comparison more straightforward, the random-errors are kept under the same assumption of nor-
mal distribution among the three models. In the absence of historical data/experiment, we spec-
ify practical weakly informative priors for all model parameters to obtain well-defined (proper)
posteriors following the recommendations in (Hobert and Casella, 1996; Zhao et al., 2006). In
particular, (i) fixed-effects are taken to be independent normal distribution N(0, 100) for each com-
ponent of the population parameter vector β. (ii) The prior for the variance-covariance matrix of the
random-effects Σb is taken to be inverse Wishart distributions IW (G2, η1) with covariance matrix
G2 = Diag(0.01, 0.01, 0.01, 0.01) and degree of freedom η1 = 5. (iii) The prior for the variance-
covariance matrix of the model errors Σ is taken to be inverse Wishart distributions IW (G3, η2)
with covariance matrix G3 = Diag(0.01, 0.01) and degree of freedom η2 = 3. (iv) For each of
the skewness parameters δ1 and δ2, independent normal distribution N(0, 100) is used to accom-
modate either positive or negative skewness, and it allows the data to determine which one is more
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appropriate. (v) Prior choice for ν is chosen as ν ∼ Exp(0.5)I(ν > 2) (i.e., exponential density
truncated at 2) to reflect a prior on ν with a well-defined and finite variance.
The MCMC sampler was implemented using WinBUGS software (Lunn et al., 2000), and the
program codes are available in Appendix C. In particular, the MCMC scheme for drawing samples
from the posterior distributions of all parameters is obtained by the Gibbs sampler. After collecting
the final MCMC samples, we are able to draw statistical inference for the unknown parameters.
Specifically, we are interested in the posterior means and quantiles. See the articles (Huang et al.,
2006; Lunn et al., 2000) for detailed discussions of the Bayesian modeling approach and the im-
plementation of the MCMC procedures, including the choice of the hyper-parameters, the iterative
MCMC algorithm, sensitivity analysis and convergence diagnostics. We propose that, after an initial
number of 50,000 burn-in iterations, every 20th MCMC sample is retained from the next 200,000.
Thus, we obtain 10,000 samples of targeted posterior distributions of the unknown parameters for
statistical inference.
4.4.2. Model comparison results
Bayesian modeling approach based on the specific model (4.10) with different model distribution
specifications from the SE class was used to fit the data. For selecting the best model that fits the
data adequately, a Bayesian selection criterion, DIC, is used. As with other model selection criteria,
we caution that DIC is not intended for identification of the “correct” model, but rather merely as
a method of comparing a collection of alternative formulations. As an alternative, we also evaluate
EPD and RSS, while the detail information related to DIC, EPD and RSS can be found in Section
2.4.1.
Table 4.1 presents the DIC, EPD and RSS values among the three competing models. It is seen
that the SN and ST Model produce better fit than the N Model in terms of DIC, EPD and RSS. In
particular, the ST Model (with the smallest DIC) offers the best fit among the N, SN and ST Modal;
these findings are consistent to those obtained by EPD and RSS criteria. Thus, we select the ST
Model as our best fit model.
Figure 4.4 shows the box-plots for the skewness parameter, δ1 and δ2, among the SN and ST
Model. The 95% CI of skewness parameters in the ST Model for both CD4 and CD8 cell count
do not include zero, which confirm significantly positive skewness of the bivariate responses. In
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Table 4.1: Model comparison using DIC, EPD and RSS criteria.
Model
Criterion N SN ST
D¯ 979.14 945.09 600.97
pD 140.58 141.91 186.02
DIC 1119.72 1086.86 788.99
EPD 0.840 0.825 0.821
RSS 690.4 128.6 127.1
the SN Model, the 95% CI of skewness parameter for CD8 cell count doesn’t include zero, while it
includes zero for CD4 cell count.
4.4.3. Estimation results based on the ST Model
Based on DIC, EPD and RSS, the best fit model is the ST Model, in which random-effects are as-
sumed to have an ST distribution. Figure 4.5 plots the marginal posterior densities of the parameter
ν for the ST Model. It shows some degree of right skewness confirming non-normal nature.
Compared with the N and SN Models, the SD for the fixed-effects parameters for both CD4
and CD8 cell count (β0 ∼ β6) from the ST Model were smaller (Table 4.2). In the ST Model, the
estimated skewness parameters for the CD4 and CD8 cell count are 0.441 and 0.518, respectively
(Table 4.2). Because the 95% posterior credible interval for both skewness parameters do not in-
clude zero (95% CI is 0.098 ∼ 0.678 for the CD4 cell count, and is 0.219 ∼ 0.833 for the CD8 cell
count), this confirms the positive skewness observed from the data. We also found the estimated
skewness parameter for the CD8 cell count was significantly higher than that for the CD4 cell count
(p < 0.0001). As expected, the results shown in Table 4.2 also indicate that there is a negative asso-
ciation between the CD4 cell count and baseline log10RNA (β(4)5 = −0.113, 95% CI is -0.208 ∼
-0.016). But we did not find any significant association between the CD8 cell count and the baseline
log10RNA (β(8)5 = 0.004, 95% CI is -0.116 ∼ 0.124). Both CD4 and CD8 cell count significantly
increase with the treatment time (95% CI is 0.282 to 0.850 for the CD4 cell count, and is 0.210 to
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Figure 4.4: Box plot of skewness parameter for the SN and ST Models. The upper panel is for CD4
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Figure 4.5: Marginal posterior densities estimates of parameter ν for the ST Model.
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0.950 for the CD8 cell count). However, no significant group difference was found.
Table 4.2: A summary of the estimated posterior mean (PM) of population (fixed-effects) param-
eters, as well as the corresponding standard deviation (SD) and lower limit (LCI ) and upper limit
(UCI ) of 95% equal-tail credible interval (CI).
CD4 β(4)0 β
(4)
1 β
(4)
2 β
(4)
3 β
(4)
4 β
(4)
5 β
(4)
6 δ1 σ
2
11 ν
N PM -0.056 0.368 0.363 0.112 0.007 -0.233 1.546 – 0.131 –
LCI -6.914 -0.100 0.053 -0.336 -0.024 -0.381 -5.618 – 0.109 –
UCI 7.066 0.837 0.678 0.545 0.038 -0.056 8.864 – 0.156 –
SD 3.506 0.238 0.158 0.224 0.016 0.081 3.516 – 0.012 –
SN PM 0.433 0.301 0.410 0.070 0.001 -0.212 1.083 0.559 0.128 –
LCI -5.893 -0.154 0.059 -0.407 -0.029 -0.337 -4.000 -0.469 0.107 –
UCI 5.639 0.750 0.762 0.544 0.029 -0.054 7.500 1.135 0.153 –
SD 3.118 0.229 0.179 0.242 0.014 0.071 3.137 0.441 0.012 –
ST PM -1.334 0.148 0.559 -0.103 0.016 -0.113 1.437 0.407 0.051 2.914
LCI -3.837 -0.199 0.282 -0.466 -0.007 -0.208 -0.809 0.098 0.035 2.072
UCI 0.841 0.513 0.850 0.259 0.035 -0.016 3.967 0.678 0.071 4.306
SD 1.261 0.179 0.144 0.184 0.011 0.049 1.298 0.148 0.009 0.602
CD8 β(8)0 β
(8)
1 β
(8)
2 β
(8)
3 β
(8)
4 β
(8)
5 β
(8)
6 δ2 σ
2
22 σ
2
12
N PM -2.108 -0.370 0.173 0.469 0.001 0.051 1.764 – 0.290 0.062
LCI -7.435 -0.949 -0.244 -0.130 -0.027 -0.115 -4.275 – 0.239 0.036
UCI 4.045 0.246 0.598 1.061 0.033 0.231 7.257 – 0.350 0.090
SD 3.097 0.304 0.213 0.303 0.015 0.087 3.254 – 0.028 0.014
SN PM -0.457 -0.286 0.227 0.404 -0.008 0.028 0.561 1.017 0.283 0.061
LCI -4.523 -0.808 -0.223 -0.257 -0.041 -0.123 -3.351 0.605 0.236 0.037
UCI 3.595 0.236 0.685 1.043 0.023 0.174 4.871 1.416 0.340 0.088
SD 2.159 0.266 0.233 0.332 0.016 0.078 2.230 0.228 0.027 0.013
ST PM -2.078 0.020 0.565 -0.027 0.002 0.004 1.860 0.518 0.120 0.037
LCI -6.275 -0.383 0.210 -0.525 -0.025 -0.120 -1.569 0.219 0.083 0.023
UCI 0.998 0.435 0.950 0.468 0.032 0.137 6.480 0.833 0.166 0.054
SD 2.072 0.211 0.188 0.252 0.014 0.062 2.177 0.157 0.021 0.008
Although the increase of CD4 cell count is expected during an effective HAART, elevated CD8
cell count is associated with HIV virologic treatment failure (Krantz et al., 2011). Figure 4.6 shows
the estimated individual coefficient of time for CD4 and CD8 cell count in the rebound and no
rebound group. The detailed definition of rebound can be found in Section 2.4.2.3. Compared with
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the rebound group, in the no rebound group, the average individual coefficient of time for CD4 cell
count is significantly higher (median value is 0.476 and 0.133, for the no rebound and rebound,
respectively. p = 0.010). While no significant difference was found in the CD8 between the two
groups (median value is 0.379 vs. 0.260, for the no rebound and rebound, respectively. p = 0.5420
). Because the maximum follow-up of A5055 study was only 6 months and even an interval of
12 months is considered as too premature to evaluate immune response to HAART (Dronda et al.,
2002), a longer follow-up might be needed in order to draw a conclusion.
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Figure 4.6: The coefficient of time for CD4 and CD8 cell count in rebound and no rebound group .
The estimated of SDs for the dispersion matrix parameter in the ST Model are smaller compared
to the Normal or SN Model (Table 4.3). This is expected because high variability, heaviness of the
tails and the skewness are interrelated to a certain extent.
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Table 4.3: A summary of the estimated posterior mean (PM) of dispersion matrix parameter, as well
as the corresponding standard deviation (SD) and lower limit (LCI ) and upper limit (UCI ) of 95%
equal-tail credible interval (CI).
Model λ11 λ22 λ33 λ44 λ12 λ13 λ14 λ23 λ24 λ34
N PM 0.556 0.323 0.904 0.528 0.245 0.088 -0.035 0.060 0.062 -0.397
LCI 0.342 0.162 0.554 0.198 0.088 -0.149 -0.303 -0.155 -0.137 -0.810
UCI 0.885 0.567 1.437 1.048 0.449 0.360 0.205 0.285 0.291 -0.109
sd 0.140 0.106 0.231 0.219 0.092 0.127 0.127 0.111 0.105 0.179
SN PM 0.340 0.235 0.320 0.314 0.116 0.071 0.048 0.022 0.091 -0.146
LCI 0.091 0.082 0.097 0.103 -0.053 -0.088 -0.166 -0.141 -0.070 -0.492
UCI 0.719 0.506 0.809 0.740 0.355 0.275 0.266 0.193 0.301 0.051
sd 0.174 0.112 0.183 0.170 0.111 0.090 0.107 0.082 0.091 0.143
ST PM 0.181 0.148 0.241 0.257 0.028 0.061 -0.023 0.002 0.056 -0.113
LCI 0.078 0.071 0.103 0.097 -0.050 -0.024 -0.152 -0.099 -0.041 -0.300
UCI 0.354 0.279 0.459 0.542 0.118 0.175 0.083 0.097 0.175 0.009
sd 0.071 0.054 0.092 0.118 0.042 0.051 0.058 0.049 0.054 0.079
4.4.4. Comparison between bivariate (CD4 and CD8) model and univariate (CD4 or CD8 )
model
It is also important to compare estimations from the bivariate linear mixed-effects models and the
ones from univariate model that CD4 and CD8 are modeled separately. Table 4.4 shows the es-
timated population parameters based on the bivariate model and univariate model under the ST
distribution.
For CD4 cell count, except the SD for the intercept, the SD of the population parameters from
the bivariate model is bigger than that from the corresponding univariate model. For example, the
SD of the skewness parameter from the bivariate model is 0.148, while it is 0.119 in the univariate
model. The estimated parameters are also different. For example, the intercept from the bivariate is
-1.334, while it is 0.175 in the univariate model; the coefficient for the time-varying drug efficacy is
only 24% in the univariate as the value in the bivariate model (0.353 vs. 1.437).
For CD8 cell count, some estimated parameters show differently between the univariate and
bivariate models. For example, the coefficient for the group is 0.020 in the bivariate, while it is
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Table 4.4: Bivariate and univariate mixed-effect models: a summary of the estimated PM of popu-
lation (fixed-effects) parameters, as well as the corresponding SD and 95% equal-tail CI.
CD4 β(4)0 β
(4)
1 β
(4)
2 β
(4)
3 β
(4)
4 β
(4)
5 β
(4)
6 δ1
Bivariate-ST PM -1.334 0.148 0.559 -0.103 0.016 -0.113 1.437 0.407
LCI -3.837 -0.199 0.282 -0.466 -0.007 -0.208 -0.809 0.098
UCI 0.841 0.513 0.850 0.259 0.035 -0.016 3.967 0.678
SD 1.261 0.179 0.144 0.184 0.011 0.049 1.298 0.148
Univariate-ST PM 0.175 0.071 0.529 -0.113 0.006 -0.127 0.353 0.409
LCI -3.226 -0.214 0.269 -0.441 -0.014 -0.219 -3.091 0.176
UCI 3.557 0.366 0.818 0.218 0.027 -0.039 3.878 0.650
SD 1.732 0.149 0.139 0.167 0.010 0.046 1.786 0.119
CD8 β(8)0 β
(8)
1 β
(8)
2 β
(8)
3 β
(8)
4 β
(8)
5 β
(8)
6 δ2
Bivariate-ST PM -2.078 0.020 0.565 -0.027 0.002 0.004 1.860 0.518
LCI -6.275 -0.383 0.210 -0.525 -0.025 -0.120 -1.569 0.219
UCI 0.998 0.435 0.950 0.468 0.032 0.137 6.480 0.833
SD 2.072 0.211 0.188 0.252 0.014 0.062 2.177 0.157
Univariate-ST PM -1.700 -0.016 0.493 0.081 -0.003 -0.025 1.897 0.502
LCI -6.133 -0.420 0.139 -0.387 -0.029 -0.152 -2.719 0.126
UCI 2.719 0.377 0.861 0.569 0.022 0.102 6.610 0.843
SD 2.234 0.202 0.184 0.241 0.013 0.064 2.367 0.183
-0.016 in the univariate model. The estimated coefficient for time for CD4 and CD8 got from the
univariate models are slightly smaller than that for the bivariate model.
4.5. Conclusion and discussion
In this chapter, we consider a Bayesian bivariate SE approach to jointly model the CD4 and CD8 cell
count in peripheral blood. The hierarchical representations given in equation 4.4 and 4.5 provide
easy model implementation by using the conventional Bayesian software WinBUGS. Using suitable
model choice criteria (DIC, EPD and RSS), among the three models, the N, SN and ST Model, we
found the ST Model had the best model fit and the related SDs for the fixed-effects parameters were
also the smallest.
The results from the ST Model confirm the positive skewness and heavy tails observed from the
raw data. Because the estimated skewness parameter for CD8 cell count was bigger than that for
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CD4 cell count, it also confirms that the distribution of the CD8 cell count in peripheral blood are
more skewed than that of the CD4 cell count. The baseline viral load (log10 RNA) was negatively
associated with the CD4 cell count, while we didn’t find such a significant association between the
baseline viral load and the CD8 cell count. Both CD4 and CD8 cell count significantly increased
with the time of the treatment. Compared with the rebound group, the average increase rate of
the CD4 cell count over time was higher in no rebound group, while no such significant difference
between the rebound and no rebound group was found in the CD8 cell count.
For hierarchical LME via Bayesian approach, one concern is that using weakly informative
priors may lead to inconsistent inferential results (Natarajan and Kass, 2000; Zhao et al., 2006).
In order to check whether the results were sensitive to the prior choice, we conducted sensitive
analysis and recomputed the posterior quantities of interest. Although slight changes in the values
of population parameters were noticed, the results were quite robust overall and the conclusions
among the three models were kept the same.
This chapter has some limitations. The AIDS clinical trial data we used only included the total
number of CD8 cells in peripheral blood. Because HIV-1 virus will not directly ‘kill’ CD8 cells, the
qualitative factors within the CD8 cells response and sub-groups of CD8 cells such as HIV specific
CD8 , naive CD8, or activated CD8 cells, may be the principal determinants of HIV/AIDS disease
progression (Migueles et al., 2002). Also, a clinical trial study with longer follow-up and ‘naive’
patients who never got HAART treatment may be a better data set for testing the proposed models
and methods.
The skewed-elliptical models applied in this study are quite flexible and can be easily extended
to a more general distribution family such as skew-normal independent (SNI) by changing the dis-
tribution of ξi in equation (4.5), for example, if we assume ξi ∼ Beta(ν, 1) and ν > 0, then it
will be multivariate skew-slash distribution. This kind of skewed modeling approach is important in
many biostatistical applications areas where either skewness should be considered or transformation
can be avoided. The method is useful for the exploring a “clustered” data, regardless of whether it
is cross-sectional or longitudinal one. We can easily apply the proposed method in WinBUGS and
building in model checking will facilitate model comparisons.
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5 Overall discussion and conclusions
This study has relaxed the normal distribution assumption in longitudinal data by using a multivari-
ate SE distribution family via Bayesian nonlinear or linear mixed-effects modeling approach. This
chapter summarizes the new development arising from this study, the contributions of this study in
terms of methodology and application, the study’s limitations, and further research goals.
In linear and nonlinear mixed-effects models, random-effects and within-subject random errors
are commonly assumed to follow a normal distribution. Although this assumption will bring con-
venience in the computation, it may be an unrealistic and obscure important features among and
within subject variation. During recent years, modifying well-known distributions by condition-
ing and transforming in order to include skewness has received much attention. Among different
versions of modified skewed distributions, we selected Sahu’s version because it can be easily ap-
plied via Bayesian approach in WinBUGS. The following summarizes the main contributions of
this dissertation.
Multiphasic HIV viral load changes since the treatment indicates that the viral decay rate is a
time-varying process. Mixed-effects models with different time-varying decay rate functions have
been proposed in the literature, however, there are two critical issues: (i) it has not been deter-
mined which model is more appropriate for practical application; (ii) the model random errors are
commonly assumed to follow a normal distribution, which may be unrealistic and can cause biased
inference. Because skewness of HIV viral load is still noticeable even after transformation, it is im-
portant to use a more general distribution family that can allow us to relax the normal assumption.
In Chapter 2, we developed the skew-elliptical Bayesian mixed-effects models by considering that
model random errors have an SE distribution. We compared the performance of different SE models
with time-varying decay rate function. We also compared the performance among the models with
normal, Student-t, SN and ST distribution. Two AIDS clinical trial data sets were used to test the
proposed models and methods. The results indicate the ST distribution model with a time-varying
function that includes two exponential components is superior to the other models. The model fit is
88
better with the assumption of ST and SN than with an assumption of normal or Student-t distribu-
tion. This finding suggests that it is important to assume a model with a skewed distribution in order
to achieve reasonable results when the data exhibit non-normality characteristic. Based on the best
fitting model under the ST distribution, we found the time-varying viral decay rate was significantly
associated with the CD4 cell count and HIV-1 viral rebound status, which may provide important
clinical information such as prediction of long-term outcome based on the early stage response.
Since we didn’t consider any covariates in Chapter 2, we extended the SE mixed-effects mod-
els in Chapter 3 such that the CD4 cell count was included as a covariate in order to account for
between- and within-subject variation. Among the models that can be used for different lengths of
HIV follow-up, we compared LME, NLME, and SNLME models. The critical question that needed
to be answered was whether these models produce coherent estimates of viral decay rates, and if
not, which model is appropriate and should be used in practice. Besides the skewed distribution
observed in the HIV viral load, CD4 cell count also shows skewness that should not be ignored
and they may be often measured with substantial errors or at different measurement schedules, in
Chapter 3 these issues are addressed simultaneously by jointly modeling the response variable with
skewness and a covariate process with measurement errors using a Bayesian approach to investi-
gate how estimated parameters are changed or different under these three models. We found that
there was a significant incongruity in the estimated decay rates in viral loads based on the three
mixed-effects models, suggesting that the decay rates estimated by using Bayesian LME or NLME
joint models should be interpreted differently from those estimated by using Bayesian SNLME
joint models. The findings also suggested that the Bayesian SNLME joint model is preferred to
other models because an arbitrary data truncation is not necessary; and it was further shown that
the models with a skew-normal distribution and/or measurement errors in covariates may achieve
reliable results when the data exhibit skewness.
In Chapter 4, multiple correlated outcomes should be estimated in a model where their depen-
dence on the independent variables can be considered. To accomplish this, the bivariate outcomes
of CD4 and CD8 cell count were jointly analyzed under BLME, while the baseline viral load, age,
time-varying drug efficacy and treatment groups were included as covariates. In HIV immunologic
responses, such as CD4 and CD8 cell count, the corresponding values often show noticeable non-
normal characteristics such as skewness with a heavy right tail. There are several limitations to
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using transformation, including reduced information, no guarantee of joint normality, no universal
transformation, or difficultly in interpreting of the results. Therefore, we applied a more flexible
class of parametric multivariate SE distributions to model CD4 and CD8 cell count. This approach
provides an appealing robust alternative to the symmetric normal process in an LME model frame-
work. The estimated results confirmed the positive skewness and heavy tails observed from the data,
while the DIC value indicated the model fitting was improved by considering these two issues. One
of the advantages of the proposed methods is the easy extension to a more general family such as
skew-normal independent distribution.
The proposed methods may have a significant impact on AIDS research from a methodology
and application standpoint of view. Given the fact that HIV-1 viral load, CD4 and CD8 cell count
all show noticeable skewness, relaxing normality assumption with skew-elliptical distribution will
allow more accurate inference of parameters with adjusting for the data with skewness. The esti-
mation is made via Bayesian MCMC approach that can be carried out by using publicly available
WinBUGS software. The theoretical and technical solutions proposed in this research are quite
general, so they can be used in other biological fields where skewness should be considered. From
an application point of view and to our best knowledge, few published articles have: (i) compared
different HIV dynamic models that can be used for the entire follow-up data with the normality
assumption being relaxed, (ii) compared HIV dynamic models used in different lengths of HIV
follow-up through a joint model that can simultaneously consider the measurement errors in the
covariates such as CD4 and skewness observed in the outcome and covariates, (iii) used CD4 and
CD8 as bivariate outcomes and accommodated normality departures (skewness and heavy tails) and
hence eliminated the need for ad hoc data transformations.
Until the late 1980s, Bayesian statistics were only considered as an interesting alternative to the
“classical” frequentist approach for several reasons. The main objection from “classical” statisti-
cians was the subjective view point via the prior distribution in Bayesian approach, which can be
easily arguable since either non-informative prior distributions can be used when no strong previous
information exists or reasonable informative prior distributions should be selected so the knowl-
edge is a developing process, therefore, no need of “building from scratch” every time. The real
obstacle that prevented Bayesian theory from being as one of the main stream approaches was the
intractability involved in the calculation of the posterior distribution. Implementation of the MCMC
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methods equipped with powerful personal computers made Bayesian statistics applicable. In HIV
dynamic models, the estimation of the parameters is complex because many times, the likelihood
has no closed form, even for simple models. Asymptotic approximation methods had provided some
solutions but may have issues such as lack of generalization or inconsistent estimates. The Bayesian
approach provides an attractive alternative solution in this field, and it allows us to build more real-
istic models with more complicated structure that may be prohibitive or at least very cumbersome
in frequentist approach.
Although the Bayesian approach has proved to be a very useful tool in the complex model in-
ference, a main concern is the uncertainty regardling the prior distributions and the initial values
selection. The basic tool for investigating model uncertainty is the sensitivity analysis. Based on
different initial values, re-computing the posterior quantities of interest can indicate whether the re-
sults have changed in a way that will significantly affect the results interpretations and conclusions.
If the results are robust against the different initial values, we can report the results with confidence
and be assured that the related conclusions are solid. The results should be explained with caution
if they are sensitive to the initial values. The sensitivity analyses in this dissertation show that the
estimated parameters were not sensitive to both prior parameters and the initial values, so the re-
sults were reasonable and robust. One thing needs to be pointed out: after we found the results
were robust to the priors and initial values, we used the same priors and initial values in the model
comparisons.
The complicated HIV pathogenesis motivated us to combine a new general distribution fam-
ily and Bayesian inference. The proposed methods enhance the modeling flexibility and allow
researchers to analyze longitudinal and multiple treatment factors in a wide variety of considera-
tions. In addition, the proposed hierarchical modeling approach can be easily implemented using
the WinBUGS package that is publicly available. These factors make our approach quite power-
ful and easily accessible to statisticians. In many biological and medical fields, non-normality is a
commonly seen phenomenon while the underlying mechanism of the outcome is always complex,
which requires advanced mathematical modeling. We believe the proposed models and methods are
quite general and helpful and can be used in other biostatistical applications.
There are several limitations in this dissertation. We did not consider missing data issue, and
due to the complex nature of HIV/AIDS and the toxicity of medications, the assumption of missing
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at random may not be a reasonable assumption. This issue may be addressed using two-step or
multiple computation methods. Below detection limit, which is left censoring, was not considered
in this study either. Another limitation involves the related biomarkers used: we examined a pooled
host cell population and did not consider the individual compartments of short-lived productively in-
fected cells, long-lived or latently infected cells; the virus compartment was not further decomposed
into infectious versus noninfectious virions.
Although the SE distributions used in this dissertation belong to a general family that includes
many commonly used distributions, ideally, it would be helpful to have an even more general
family that can be used to develop a Bayesian analysis of censored mixed-effects models. Skew-
normal/independent (SNI) distribution is an attractive class of asymmetric heavy-tailed distributions
that includes the skew-normal, the skew t, skew slash and the skew-contaminated normal distribu-
tions as special cases. As viral decay rates reflect the potency of antiviral regimens, it is important
to evaluate the regimen’s effect on long term responses. Besides the binary endpoint used in this
research (rebound vs. no rebound), the long term responses can be survival endpoints such as time
to HIV-1 RNA falling below the detection limit, time to virological failure or time to progression to
AIDS. The estimated viral decay rates can be treated as covariates and because frequent evaluations
may not be common during long-term follow-up, the event will be known only to have occurred
within some interval of time (interval censoring). Rebound is generally caused by emergence of a
drug-resistant virus strain, and it is important to develop a flexible, yet parsimonious mechanistic
model to predict the rebound. By Extending basic HIV dynamic model, the latent HIV dynamic
model can be use via Bayesian MCMC-SAEM algorithm. There is marked variation in how the
body responds to the virus , and in the time-course of progression to AIDS. It is known that host
genetic differences contribute to this variation, but our knowledge of the relevant host genetic fac-
tors is currently limited. Systematic searches of the genome to identify common genetic variants
(genotypes) that influence the human response to HIV-1 is promising approach.
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Appendix A: WinBUGS Code for ST-Model IV-Equation (2.12) in Chapter 2
## Begin of model
model
{
for (i in 1:N)
{
## parametric random effects of normal-Response model
b2[i,1] <- 0
b2[i,2] <- 0
b2[i,3] <- 0
b2[i,4] <- 0
b2[i,5] <- 0
b[i,1:5] ˜dmnorm(b2[i,1:5],Omega2[,])
nbeta1[i]<- beta[1]+b[i,1]
nbeta2[i]<- beta[2]+b[i,2]
nbeta3[i]<- beta[3]+b[i,3]
nbeta4[i]<- beta[4]+b[i,4]
nbeta5[i]<- beta[5]+b[i,5]
## Individual parameter estimates
}
for (j in 1 : M)
{
## Main components of response based on ST
beta1[j] <- beta[1]+b[y[j,4],1]
beta2[j] <- beta[2]+b[y[j,4],2]
beta3[j] <- beta[3]+b[y[j,4],3]
beta4[j] <- beta[4]+b[y[j,4],4]
# y[j,4]= id
beta5[j] <- beta[5]+b[y[j,4],5]
#decay rate for Model IV
decay[j] <- (beta2[j]*exp(-beta3[j]*y[j,6]) +
beta4[j]*exp(-beta5[j]*y[j,6]) )
dm1[j] <-beta1[j] -decay[j]*y[j,6]
# y[,6]= time(day)
## skew-T distribution to t sidtribution
w[j] ˜ dt(0, 1,nu) I(0,)
mu[j] <- dm1[j] + delta*w[j]
# ST distribution
aau[j] <- (nu+w[j]*w[j])/n1*eta
y[j,12] ˜ dt(mu[j],aau[j],n1)
# y[,12]=logeRNA
Y.pred[j] ˜ dt(mu[j],aau[j],n1)
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# predicted values
## Fitted values and Residuals
fit[j] <- mu[j]
resid[j] <- y[j,12]-fit[j]
sresid[j] <- sqrt(eta)*(y[j,12]-fit[j])
ssr.r[j] <- pow(resid[j],2)
# squares of residuals
sssr.r[j] <- pow(sresid[j],2)
# squares of SR
ssr.Y.obs[j]<-pow((Y.pred[j]-y[j,12]),2)
}
SSR <-sum(ssr.r[])
# sum of squares of residuals
SSSR <- sum(sssr.r[])
# sum of standardized squares of residuals
SSR.pred <- mean(ssr.Y.obs[])
# EPD
## Prior distributions of the hyperparameters
# (0) Degree of freedom
nu0<-0.1
nu ˜ dexp(nu0) I(2,)
n1<-nu+1
# (1) Coefficients
for (l in 1:5){ beta[l]˜dnorm(0,1.0E-2)}
# (3) Skew-t random effects
delta ˜ dnorm(0.0, 0.01)
# (4) Variance-covariance matrice
Omega2[1:5,1:5] ˜dwish(R2[,],5)
v2[1:5,1:5] <- inverse(Omega2[,])
# (5) Precision parameters
eta ˜dgamma(0.01,0.01)
sigma <- 1/eta
}
## End of model
## Data inputed
list(N=44, M=274,
R2 = structure(
.Data = c(1,0, 0, 0, 0,
0,1, 0, 0, 0,
0,0, 1, 0, 0,
0,0, 0, 1, 0,
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0,0, 0, 0, 1),
.Dim = c(5, 5)))
## Initial values
list(beta=c(4.54, -5.55, 5.00, 0.5, 1),nu=10,delta=1.5, eta=1,
Omega2= structure(
.Data = c( 1.94 , 1.00, -0.56, -0.58, -0.45,
1.00, 7.03, -1.08, -3.93, -1.08,
-0.56, -1.08, 1.30, 2.74, 0.69,
-0.58, -3.93, 2.74, 8.75, 2.07,
-0.45, -1.08, 0.69, 2.07, 0.66),
.Dim = c(5, 5)))
## End of program
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Appendix B: WinBUGS Code for Model I in Chapter 3
# Model I: Skew-Normal Bayesian Semiparametric
# Nonlinear Mixed-Effects
# (SN-BSNLME) Model in conjunction with the
# semiparametric biexponential
# model (3.3)}.
model{
for (i in 1:44) {
a2[i,1] <- 0
a2[i,2] <- 0
a2[i,3] <- 0
a2[i,4] <- 0
a3[i,1] <- 0
a3[i,2] <- 0
a3[i,3] <- 0
b[i,1:4]˜dmnorm(a2[i,1:4], Sigma2[,])
a[i,1:3]˜dmnorm(a3[i,1:3], Sigma3[,])
}
for (j in 1:310) {
## modeling true CD4 via measurement error model
z.star[j] <-(alpha[1]+a[y[j,4],1]) +
(alpha[2]+a[y[j,4],2])*y[j,13] +
(alpha[3]+a[y[j,4],3])*y[j,13]*y[j,13]+
delta2*w2[j]
w2[j] ˜dnorm(0,1)I(0,)
y[j,11]˜dnorm(z.star[j],tau2)
## Viral load response model associated with true CD4 covariate
betai1[j] <-beta[1] +b[y[j,4],1]
betai2[j] <-beta[2] +b[y[j,4],2]
betai3[j] <-beta[3] +b[y[j,4],3]
betaij4[j] <-beta[4] +beta[5]*z.star[j]
+mu.not[1]*Z[j,2]+mu.not[2]*Z[j,3]+b[y[j,4],4]
dm1[j] <-betai1[j]-step(betai2[j]-betaij4[j])*betai2[j]*y[j,13]
dm2[j] <-betai3[j]-step(betai2[j]-betaij4[j])*betaij4[j]*y[j,13]
dm3[j] <-exp(dm1[j])
dm4[j] <-exp(dm2[j])
dm5[j] <-dm3[j] +dm4[j]
mu[j] <-log(dm5[j]) +delta*w[j]
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w[j]˜dnorm(mu[j],tau)
y[j,10]˜dnorm(mu[j],tau) # SN
## Fitted values and residues
fit[j] <-mu[j]
res[j] <-y[j,10]-fit[j]
}
## prior distributions of the hyperparameters:
# 1. coefficients
for(l in 1:5) {beta[l]˜dnorm(0, 1.0E-2)}
for(l in 1:2) {mu.not[l]˜dnorm(0, 1.0E-2)}
for(k in 1:3) {alpha[k]˜dnorm(0, 1.0E-2)}
# 2. Precision parameters
tau˜dgamma(0.01, 0.01)
sigma.tau <- 1/tau
tau2˜dgamma(0.01, 0.01)
sigma.tau2 <- 1/tau2
# 3. Variance-cvoariance matrices
Sigma2[1:4,1:4]˜dwish(R2[,],5)
v2[1:4,1:4] <-inverse(Sigma2[,])
Sigma3[1:3,1:3]˜dwish(R3[,],5)
v3[1:3,1:3] <-inverse(Sigma3[,])
# 4. skewness parameters
delta˜dnorm(0.0,0.01)
delta2˜dnorm(0.0,0.01)
}
## Data
list(R2=structure(.Data=c(1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1),
.Dim=c(4,4)),R3=structure(.Data=c(1,0,0,0,1,0,0,0,1), .Dim=c(3,3)))
#initial values
list(beta=c(5, 4, 3.4, 4.0, 1.5, 4.2),
alpha=c(0,0,0),mu.not=c(0,0),delta=0.5,
delta2=0.5,tau=1, tau2=1,
Sigma2=structure(.Data=c(1.229, 0.043, -0.750, 0.710,
0.043, 0.090, 0.002, -0.013,
-0.750, -0.002,1.059, -0.214,
0.170, -0.013,-0.214, 0.120),
.Dim=c(4,4)),
Sigma3=structure(.data=c(.1,0, 0, 0,.1, 0, 0, 0,.1), .Dim=c(3,3)))
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Appendix C: WinBUGS Code for ST Bivariate Model-Equation (4.5) in Chapter 4
model
{
for (i in 1:N)
{ u.b[i] ˜ dgamma(db,db)
# random effects for bivariate model
# correlation between Cd4 and CD8 is
incorporated in random effects and model errors
for (k in 1:2)
{ b1[i,k] <- 0
w.b1[i,k]˜dnorm(b1[i,k], R.a[k,k]) I(0,)
w.b[i,k]<-w.b1[i,k]/sqrt(u.b[i])
b1.b[i,k]<-delta1*(w.b[i,k]-mub)
}
for (k in 3:4)
{ b1[i,k] <- 0
w.b1[i,k]˜dnorm(b1[i,k], R.a[k,k]) I(0,)
w.b[i,k]<-w.b1[i,k]/sqrt(u.b[i])
b1.b[i,k]<-delta2*(w.b[i,k]-mub)
}
for (k in 1:4)
{
for (l in 1:4)
{
Omegab[i,k,l]<-Omega[k,l]*u.b[i]
}
}
b[i,1:4] ˜dmnorm(b1.b[i,1:4],Omegab[i,,])
}
for (j in 1 : M)
{ # ST-Bivariate CD4 and CD8 LME model
beta1[j] <-beta[1] +beta[2]*y[j,2]+b[y[j,4],1]
#y[j,2]=arm
beta2[j] <-beta[3] +beta[4]*y[j,2]+b[y[j,4],2]
#y[j,4]=id
alpha1[j] <-alpha[1] +alpha[2]*y[j,2]+b[y[j,4],3]
#y[j,2]=arm
alpha2[j] <-alpha[3] +alpha[4]*y[j,2]+b[y[j,4],4]
#y[j,4]=id
cd[j,1] <-beta1[j] + beta2[j]*y[j,6] +beta[5]*y[j,17]
+beta[6]*y[j,20] +beta[7]*y[j,18]
cd[j,2] <-alpha1[j] + alpha2[j]*y[j,6] +alpha[5]*y[j,17]
+alpha[6]*y[j,20] +alpha[7]*y[j,18]
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# y[j,6]=scaled time (0,1); y[j,17] =age;
# y[j,20]=baseline ln(RNA); y[j,18]=eff
for (k in 1:2){
for (l in 1:2)
{
O1[j,k,l]<-Omega1[k,l]*u.b[y[j,4]]
}
}
y[j,15:16]˜dmnorm(cd[j,1:2], O1[j,,])
# y[j,15]=CD4, y[j,16]=CD8
Y.pred[j,1:2]˜dmnorm(cd[j,1:2], O1[j,,])
}
# Prior distributions of the hyperparameters
# (0) Degree of freedom
nub˜ dexp(0.1) I(2,)
nb<-nub+1
mub<- exp(loggam(0.5*(nub-1.))-
loggam(0.5*nub))*sqrt(nub/3.14159)
db<-0.5*nub
# (1) Coefficients
for (l in 1:7)
{ beta[l]˜dnorm(0,0.01)
alpha[l]˜dnorm(0,0.01)}
# (2). Variance-covariance matrice for model errors
Omega1[1:2,1:2] ˜dwish(R1[,],3)
v1[1:2,1:2] <- inverse(Omega1[,])
# (3) Variance-covariance matrice for random effects
Omega[1:4,1:4] ˜dwish(R[,],5)
v[1:4,1:4] <- inverse(Omega[,])
# (4). Skewness parameters
delta1˜dnorm(0,0.01)
delta2˜dnorm(0,0.01)
}
## End of model
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Appendix D: WinBUGS Code for ST Univariate Model for CD4 in Chapter 4
## Begin of model
model
{
for (i in 1:N)
{
u.b[i] ˜ dgamma(db,db) # for random effects of bivariate model
# Random effects for bivariate model
for (k in 1:2)
{ b1[i,k] <- 0
w.b1[i,k]˜dnorm(b1[i,k], R.a[k,k]) I(0,)
w.b[i,k]<-w.b1[i,k]/sqrt(u.b[i])
b1.b[i,k]<-delta1*(w.b[i,k]-mub)
}
for (k in 1:2){
for (l in 1:2)
{
Omegab[i,k,l]<-Omega[k,l]*u.b[i]
}
}
b[i,1:2] ˜dmnorm(b1.b[i,1:2],Omegab[i,,])
}
for (j in 1 : M)
{ # Univariate LME model for CD4
beta1[j] <-beta[1] +beta[2]*y[j,2]+b[y[j,4],1]
#y[j,2]=arm
beta2[j] <-beta[3] +beta[4]*y[j,2]+b[y[j,4],2]
#y[j,4]=id
cd4[j] <-beta1[j] + beta2[j]*y[j,6] +beta[5]*y[j,17]
+beta[6]*y[j,20] +beta[7]*y[j,18]
# y[j,6]=scaled time (0,1); y[j,17] =age;
# y[j,20]=baseline ln(RNA); y[j,18]=eff
au4[j]<-u.b[y[j,4]]*tau1
y[j,15] ˜dnorm(cd4[j], au4[j])
# y[,j,15] =standarized CD4
Y.predcd4[j]˜dnorm(cd4[j], au4[j])
# Fitted values and Residuals
fitcd4[j] <- cd4[j]
residcd4[j] <- y[j,15]-fitcd4[j]
sresidcd4[j] <- sqrt(tau1)*(y[j,15]-fitcd4[j])*sqrt(1- 2/nub)
ssr.cd4[j] <- pow(residcd4[j],2)
# SR of CD4
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sssr.cd4[j] <- pow(sresidcd4[j],2)
# SSR of CD4
ssr.Pcd4[j]<-pow((Y.predcd4[j]-y[j,15]),2)
# squares of predicted value
}
SSR.CD4 <- sum(ssr.cd4[])
# sum of SR of CD4
SSSR.CD4 <- sum(sssr.cd4[])
# sum of SSR of CD4
SSRP.CD4<- mean(ssr.Pcd4[])
# EPD of CD4
## Prior distributions of the hyperparameters
# (0) Degree of freedom
nub˜ dexp(0.1) I(2,)
nb<-nub+1
mub<- exp(loggam(0.5*(nub-1.))-loggam(0.5*nub))*sqrt(nub/3.14159)
db<-0.5*nub
# (1) Coefficients
for (l in 1:7)
{beta[l]˜dnorm(0,0.01)}
# (2). Precision parameters
tau1˜dgamma(0.01,0.01)
sigma1 <- 1/tau1
# (3) Variance-covariance matrice
Omega[1:2,1:2] ˜dwish(R[,],5)
v[1:2,1:2] <- inverse(Omega[,])
# (4). Skewness parameters
delta1˜dnorm(0,0.01)
}
## End of model
# Data
list(N=44, M=310,
R = structure(
.Data = c(1, 0.5,
0.5, 1),
.Dim = c(2,2)),
R.a= structure(
.Data=c(1,0,
0,1),
.Dim = c(2,2)))
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